IRACEMA NUNES DE BARROS

Diversidade molecular e evolução in vitro de coronavírus canino (CCoV)

São Paulo 2015

IRACEMA NUNES DE BARROS

Diversidade molecular e evolução in vitro de coronavírus canino (CCoV)

Tese apresentada ao Programa de Pós-Graduação em Epidemiologia Experimental Aplicada às Zoonoses da Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo para obtenção do título de Doutor em Ciências

Departamento:

Medicina Veterinária Preventiva e Saúde Animal

Área de Concentração:

Epidemiologia Experimental Aplicada às Zoonoses

Orientador:

Prof. Dr. Paulo Eduardo Brandão

Autorizo a reprodução parcial ou total desta obra, para fins acadêmicos, desde que citada a fonte.

DADOS INTERNACIONAIS DE CATALOGAÇÃO-NA-PUBLICAÇÃO

(Biblioteca Virginie Buff D'Ápice da Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo)

Г

T.3099 FMVZ	Barros, Iracema Nunes de Diversidade molecular e evolução <i>in vitro</i> de coronavírus canino (CCoV) / Iracema Nunes de Barros 2015. 73 f. :il.
	Tese (Doutorado) - Universidade de São Paulo. Faculdade de Medicina Veterinária e Zootecnia. Departamento de Medicina Veterinária Preventiva e Saúde Animal, São Paulo, 2015.
	Programa de Pós-Graduação: Epidemiologia Experimental Aplicada às Zoonoses. Área de concentração: Epidemiologia Experimental Aplicada às Zoonoses.
	Orientador: Prof. Dr. Paulo Eduardo Brandão.
	1. CCoV. 2. Molecular. 3. Sequenciamento. 4. Isolamento. 5. Evolução. I. Título.





FACULDADE DE MEDICINA VETERINÁRIA E ZOOTECNIA

Comissão de Ética no uso de animais

CERTIFICADO

Certificamos que o Projeto intitulado "Diversidade molecular e evolução in vitro de coronavírus canino (CCoV)", protocolado sob o nº 2188/2011, utilizando 100 (cem) cães, sob a responsabilidade do(a) Prof. Dr. Paulo Eduardo Brandão, está de acordo com os princípios éticos de experimentação animal da "Comissão de Ética no uso de animais" da Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo e foi aprovado em reunião de 18/5/2011.

We certify that the Research "Molecular diversity and in vitro evolution of canine coronavirus (CCoV)", protocol number 2188/2011, utilizing 100 (one hundred) dogs, under the responsibility Prof. Dr. Paulo Eduardo Brandão, agree with Ethical Principles in Animal Research adopted by "Ethic Committee in the use of animals" of the School of Veterinary Medicine and Animal Science of University of São Paulo and was approved in the meeting of day 05/18/2011.

São Paulo, 19 de maio de 2011.

Profa. Dra. Denise Tabacchi Fantoni Presidente

Av. Prof. Dr. Orlando Marques de Paiva, nº87 Cidade Universitária "Armando de Salles Oliveira" São Paulo/SP – Brasil 05508-270



FOLHA DE AVALIAÇÃO

Autor: BARROS, Iracema Nunes de

Título: Diversidade molecular e evolução in vitro de coronavírus canino (CCoV)

Tese apresentada ao Programa de Pós-Graduação em Epidemiologia Experimental Aplicada às Zoonoses da Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo para obtenção do título de Doutor em Ciências

Data: ___/___/

BANCA EXAMINADORA

Prof. Dr		
Instituição:	Julgamento:	
Prof. Dr		
Instituição:	Julgamento:	
Prof. Dr		
Instituição:	Julgamento:	
Prof. Dr		
Instituição:	Julgamento:	
Prof. Dr		
Instituição:	Julgamento:	

À minha mãe, *Rejare* ou mais conhecida por *Jare*, exemplo de força, superação, e amor incondicional, que sempre me apoiou quando todos achavam que era impossível.

Agradecimentos

À Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) pela concessão da bolsa de doutorado (Processo (#2010/19399-2).

Ao **Prof. Dr. Paulo Eduardo Brandão** por todos os ensinamentos e confiança, exemplo de sabedoria, e principalmente paciência.

A toda minha família, em especial Jane e Eduardo Mouco, pelo apoio e paciência.

Á minha "cãopanheira", filha canina e amiga **Pepper**, sempre ao meu lado para me acalmar e trazer alegrias.

Á **Sheila Oliveira S. Silva** que desde o estágio curricular esteve ao meu lado como melhor amiga e parceira de trabalho, sempre com dedicação, amizade e disposição em ajudar.

Aos Prof. Dr. Leonardo José Richtzenhain e Prof. Dr. Fábio Gregori pelos ensinamentos.

Aos **Prof.s Dr.s Nicola Decaro, Vitto Martella, Maria Tempesta, Michelle Camero, Gabriella Elia, Marialaura, Canio Buonavoglia** entre outros; funcionários e estudantes **Gianvito, Ângela, Vittorio, Donatto Persici e Rafael Ramos;** por me acolherem no Laboratório de doenças infecciosas da Faculdade de Veterinária da Universidade de Bari e pela oportunidade de convívio e aprendizado.

À Sueli A. Taniwaki pela amizade e conhecimentos nos momentos finais deste estudo.

Todos os amigos e funcionários do VPS que são muitos para citar, mas reconheço todos pela amizade e convivência.

Aos funcionários da secretária do VPS-FMVZ-USP, **Cris, Danival** e **Vírginia** pela paciência, auxílio e prontidão.

Aos **Proprietários** e **Veterinários** que gentilmente contribuíram com o estudo. Principalmente, Rosely Bianca (mãe paulista), Geici, Alexandra Rosa da Silva e Luciane Pinto.

A todos que direta ou indiretamente fizeram parte desta longa jornada, mas que aqui não foram mencionados, meus sinceros agradecimentos.

"Nem tudo o que pode ser contado conta, e nem tudo o que conta pode ser contado."

(Albert Einstein)

PREFÁCIO

O trabalho aqui apresentado como Tese de Doutorado foi subdivido em três artigos já no formato dos periódicos com opção *Open-Access* às quais serão posteriormente submetidos. O trabalho foi assim escrito para incentivar a produção científica e valorizar o trabalho acadêmico e de acordo com as normas do novo regimento do Programa de Pós-Graduação e Epidemiolgia Experimetal Aplicada da FMVZ USP.

Cada artigo contém resumo, palavras-chave, materiais e métodos, discussão, conclusão e referências de acordo com a revista selecionada. Entretanto, os mesmos ainda não foram submetidos aos respectivos periódicos em função da necessidade de aprimoramento das análises de dados, sobretudo em termos evolutivos, ainda não concluídas em função do longo tempo laboratorial tomado pela execução do trabalho, além da intenção de se submeter os mesmos a revisão profissional de Inglês.

Em suma, o trabalho apresenta os seguintes tópicos:

- Resumo em português e inglês (*abstract*) contendo os objetivos, principais aspectos e resultados da tese e conclusões.
- Sumário
- Artigo 1 "Canine coronavirus (CCoV), a neglected pathogen: association with Canine parvovirus (CPV) and molecular diversity of genes S, M, N and 3b."
- Artigo 2 "Isolation of a putatively pantropic type II canine coronavirus strain in A72 cells"
- Artigo 3 "In vitro evolution of CCoV-II based on partial spike gene markers"

RESUMO

BARROS, I. N. **Diversidade molecular e evolução** *in vitro* **de coronavírus canino (CCoV).** [Molecular diversity and *in vitro* evolution of canine coronavirus (CCoV)]. 2015. 73 f. Tese (Doutorado em Ciências) – Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, São Paulo, 2015.

O coronavírus canino (CCoV) causa gastroenterite em cães jovens, podendo ser letal, sobretudo quando há coinfecção com parvovírus canino (CPV). Os objetivos do presente projeto foram investigar a presença de CCoV e CPV em amostras fecais de cães jovens; estudar a diversidade molecular das amostras de CCoV com base em sequenciamento parcial dos genes M, S, 3b e N, incluindo amostras vacinais, e estudar a evolução in vitro de CCoV em células A72 de fibroma canino. Foram detectados 40,17% (47/117) animais positivos para CCoV e 13,68% (16/117) para CPV. Estudos filogenéticos demonstraram que oito amostras foram classificadas como CCoV-II, vinte e cinco como CCoV-I. Análises para o gene M destacaram alta identidade de CCoV-I com amostras de coronavírus da peritonite infecciosa felina (PIF) e uma possível amostra pantrópica foi demonstrada pela análise do gene S. O gene do nucleocapsídeo de CCoV é altamente conservado entre os tipos I e tipo II, com uma resolução mais baixa em relação a árvores para os genes M e S. Amostras dos tipos I e II apresentam um polimorfismo baixo para o gene 3b, sem marcadores estáveis para diferenciação dos tipos de CCoV. Uma amostra de CCoV-II putativamente pantrópica foi isolada em células A72, resultando em efeito citopático no 5º dia da 5a passagem. No estudo evolutivo, a amostra vacinal CCV 1-71 e nove passagens desta em células A72 foram submetidas a amplificação parcial e clonagem molecular do gene S seguida de sequenciamento de DNA. Os resultados mostraram mutações não silenciosas, silenciosas e três deleções de aminoácidos, mas nenhuma mutação compartilhada entre as diversas passagens. Amostras vacinais de CCoV-II adaptadas em células podem ser altamente geneticamente estáveis após passagens em série em uma mesma linhagem celular, acumulando substituições de nucleotídeos principalmente sinônimas no gene S devido a relação célula - hospedeiro estável. Estes resultados de epidemiologia molecular e processos evolutivos de CCoV podem servir para uma melhor compreensão da virologia básica e ser base de dados para estudos em outros coronavírus.

Palavras-chave: CCoV. Molecular. Sequenciamento. Isolamento. Evolução.

ABSTRACT

BARROS, I. N. **Molecular diversity and** *in vitro* **evolution of canine coronavirus (CCoV)** [Diversidade molecular e evolução *in vitro* de coronavírus canino (CCoV).]. 2015. 73 f. Tese (Doutorado em Ciências) – Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, São Paulo, 2015.

Canine coronavirus (CCoV) causes gastroenteritis in young dogs and can be lethal, especially when there is co-infection with canine parvovirus (CPV). The objectives of this project were to investigate the presence of CCoV and CPV in stool samples from young dogs, the molecular diversity of CCoV strains based on partial sequencing of genes M, S, N and 3b, and the in vitro evolution of CCoV in A72 canine fibroma. Of the fecal samples studied, 40.17% animals (47/117) were positive for CCoV and 13.68% (16/117) for CPV. Phylogenetic studies have shown that eight strains were CCoV-II and twenty five CCoV-I. Phylogenetic analysis for the *M* gene highlighted the high identity of CCoV-I strains with a feline coronavirus strain (FCoV) that causes feline infectious peritonitis (FIP). Further analysis based on the spike gene showed a putative pantropic CCoV strain (CCoV-II/dog50). CCoV nucleocapsid gene is highly conserved among type I and type II, with a lower resolution relative to trees based on M and S genes. CCoV Types I and II had a low polymorphism for 3b gene, without any stable markers to differentiate thee types. Regarding the virus isolation trial, a putative pantropic CCoV-II strain was successfully isolated in A72 cells from, resulting in cytopathic effect on the 5th day of the 5th passage. In the evolutionary study, the vaccine strain CCV 1-71 and nine passages of this strain in A72 were submitted to partial S gene amplification and molecular cloning followed by DNA sequencing. Missense, silent, and three amino acids deletions were found amongst diverse clones of each passage, but no mutation was repeatedly found among passages. Cell culture-adapted CCoV-II vaccine strains can be highly genetically stable upon serial passage in a same cell line, accumulating primarily synonymous nucleotide substitutions in the S gene due to a stable cell-host relationship. In short, all data gathering herein on molecular epidemiology and evolutionary processes of CCoV can serve for a better understanding of basic virology and as a basis for studies on other coronaviruses.

Keywords: CCoV. Molecular. Sequencing. Isolation. Evolution.

SUMÁRIO

SSOCIATION WITH CANINE PARVOVIRUS (CPV) AND
IOLECULAR DIVERSITY OF GENES S, M, N AND 3B
NTRODUCTION
IATERIAL AND METHODS
FECAL SAMPLES AND CONTROLS
RNA AND DNA EXTRACTION
SYNTHESIS OF COMPLEMENTARY DNA (cDNA) OF CCoV
POLYMERASE CHAIN REACTION
STATISTICAL ANALYSIS
DNA SEQUENCING.
PHYLOGENETIC ANALYSIS
ESULTS
EFERENCES
COLATION OF A DUTATIVELY DANTDODIC TYDE II CANINE
SOLATION OF A PUTATIVELY PANTKOPIC TYPE II CANINE
UKUNA VIKUS SI KAIN IN A72 CELLS
ATEDIAL AND METHODS
EECAL SAMPLES AND C_{OV} MOLECHIAD TVDING
VIPUS ISOLATION
ISCUSSION
'ONCLUSION
FFERENCES
IN VITRO EVOLUTION OF CCoV-II BASED ON PARTIAL SPIKE
GENE MARKERS CELLS
NTRODUCTION
IATERIAL AND METHODS
CCoV STRAIN AND CELL LINE.
SERIAL PASSAGES OF CCoV
RNA EXTRACTION AND RT-PCR
DNA CLONING AND SEQUENCING
SEQUENCES ANALYSIS
ESULTS
ISCUSSION
DISCUSSION

I. Canine coronavirus (CCoV), a neglected pathogen: association with Canine parvovirus (CPV) and molecular diversity of genes S, M, N and 3b.

Barros, I.N.B. ^{1,2}; Pinto, L.D.³; Kuroda, R.B.S. ¹; Silva, S.O.S.¹; Richtzenhain, L.J. ^{1,2}, Canal, C.W.³; Brandão, P.E. ^{1,2}.

¹Department of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine, USP, Av. Prof. Dr. Orlando Marques de Paiva, 87, CEP 05508 270 - Cidade Universitária São Paulo/SP – Brasil; ²Coronavirus Research Group, USP, Av. Prof. Dr. Orlando Marques de Paiva, 87, CEP 05508 270 - Cidade Universitária São Paulo/SP – Brazil; ³ Laboratory of Virology, School of Veterinary Medicine, University of Rio Grande do Sul, Brazil; E-mail: cemavet@usp.br

ABSTRACT

Gastroenteritis is common in young dogs and is caused chiefly by canine coronavirus (CCoV) and canine parvovirus (CPV). CPV is considered the most important cause of diarrhea by veterinarian clinicians. However, studies have shown an increasing prevalence and importance of CCoV around the world, and fatal CCoV infections have been described, but there's a gap on the information regarding the molecular diversity of CCoV in many parts of the world. In this study, canine fecal samples from diverse States of Brazil were submitted to PCRs screening for CCoV and CPV, and CCoV positive samples were submitted to partial sequencing of membrane (M), spike (S), nucleotide (N), non-structural protein 3b (NS3b) genes. Of the samples collected, 40.17% (47/117) were positive for CCoV and 13.68% (16/117) for CPV; 57.45% (27/47) of CCoV infected animals showed enteritis and most of them were younger than 3 months (36/47) and unvaccinated animals (35/47). Regarding CVP,

13.68% (16/117) were positive. On these CPV positive animals, 37.5% (6/16) were coinfected with CCoV and 87.5% (14/16) had enteritis Distance genealogy and sequence identity matrix using CCoV sequences from GenBank for M gene showed the strain of the positive control and eight strains from fecal samples were included in the same group of CCoV-II strains, and twenty six were included in CCoV-I group for nt and aa trees. Results of this study can highlight the high identity of CCoV-I strains with feline coronavirus (FCoV) and showed a putatively pantropic CCoV-II strain (CCoV-II/dog50).

Keywords: Canine; coronavirus; parvovirus; enteritis; detection; sequencing;

1. Introduction

Symptomatic enteritis is common and the most important etiologic agents are canine parvovirus (CPV) and canine coronavirus (CCoV) (Parrish et al., 1991; Tupler et al., 2012). Fatal enteritis might also occur as a result of co-infections by these two viruses (Pratelli et al., 1999; Evermann et al., 1988; Zicola et al., 2012). However, mortality associated with CCoV in the absence of CPV infection has been reported in young dogs (Evermann et al., 2005), and later in 2007 and a highly virulent CCoV strain (CB/05) is extremely lethal as a result of systemic spread Decaro et al (2007).

CCoV (*Nidovirales: Coronaviridade: Coronavirinae: Alphacoronavirus: Alphacoronavirus 1*) is a single-stranded positive-sense RNA virus and has a genome consisting of genes encoding the structural proteins spike (S), envelope (E), membrane (M) and nucleocapsid (N); in addition to ORFs translated into non structural proteins, as replicase polyprotein (ORF1 - open read frame 1), 3a, 3b, 3c, 7a and 7b (Masters and Perlman, 2013; ICTV, 2014). CPV (*Parvoviridae*: *Parvovirinae*: for CPV type I *Bocavirus*: *Carnivore bocaparvovirus 1*; for CPV type II *Protoparvovirus*: *Carnivore protoparvovirus 1*) has single-stranded DNA genome of negative polarity, about 5200 nucleotides in length; the icosahedral viral capsid is 26 nm diameter, consisting of three proteins VP1, VP2 and VP3. The VP1 and VP2 proteins constitute the majority of the viral capsid (Reed et al., 1988; Park et al., 2007; ICTV, 2014).

Two different genotypes of CCoV have been recognized, CCoV type-I, with a high identity with feline coronavirus (FCoV), and CCoV type-II, divided in two subtypes, CCoV-IIa and CCoV-IIb, the former being the pantropic type (Decaro et al., 2007; Decaro et al. 2009, Decaro 2010; Pratelli et al., 2001; Pratelli et al., 2002). Later, other authors reported infection with pantropic CCoV IIa and IIb in Greek, Ireland, Japan, France and Belgium (Ntafis et al., 2010; McEligott et al., 2011; Soma et al., 2011; Zicola et al, 2012), demonstrating the widespread of this CCoV infection.

However, there are few studies about the frequency of CCoV in feces of dogs (Castro et al, 2010; Castro et al, 2013) and little data on the molecular diversity of CCoV strains is available from many parts of the world, including Brazil (Guirao et al., 2013; Pinto et al., 2014; Costa et al, 2014; Gizzi et al., 2014).

This study aimed to investigate the presence of CCoV and CPV in canine fecal samples using RT- PCR assays and to the molecular diversity of CCoV strains based on the genes of membrane (M), spike (S) and nucleocapsid (N) structural proteins and non-structural protein 3b (NS3b).

2. Materials and Methods

2.1. Fecal samples and controls

A total of 117 fecal samples from dogs (Table 1) were collected from 2009 to 2014 and stored at - 80°C until the time of testing with or without symptomatic enteritis, different breeds, genders and ages, from five Brazilian States (Pernambuco n=3; 27 from Mato Grosso n=27; Rio Grande do Sul n=18 and São Paulo n=72) (Fig. 1).

CCV 1-71 (ATCC VR 809) and CPV-2 Cornell 780916 (ATCC VR-953) strains (10^{4.03} TCID50/mL and 10^{6.66} TCID50/mL, respectively), were kindly provided by the Biovet Laboratories, Brazil, and used as positive controls for RT-PCR. As negative control, ultra-pure water treated with 0.1% diethylpyrocarbonate (DEPC water) was used.

Fig.1. Map of Brazil showing the Sates in which fecal samples of dogs were collected during this study



2.2. RNA and DNA Extraction

Fecal samples were prepared as 20% (v/v) suspensions in DEPC water and clarified at $5,000 \times g / 15$ min at 4 ° C, taking the supernatant as a sample. Total RNA and DNA from fecal samples supernatants and controls was performed with TRIzol ReagentTM (Life Technologies) as per manufacturer's instructions and by the phenol/chloroform methods as described by (Mesquita et al., 2001).

2.3. Synthesis of complementary DNA (cDNA) of CCoV

For cDNA synthesis, 3.5 μL of the extracted RNA were denatured at 95°C for 5 minutes, and then added to the reverse transcription mix containing 1 x First Strand Buffer (Life Technologies), 1 mM of each dNTP, 10 mM DTT, 25ng Random PrimersTM (Life Technologies) 100U of M-MLV Reverse TranscriptaseTM (Life Technologies TM) and DEPC water q.s.p 10μL and incubated at 37°C for 60 minutes.

2.4. Polymerase chain reaction

PCRs were carried out with 12.5 μ L of GoTaq[®] Green Master MixTM (Promega), and 2.5 μ L of each cDNA for CCoV or DNA for CPV in separate reactions, 1.25 μ L of each respective primer at 10 μ M (Tables 2 and 3) and 7.5 μ L of DEPC water to a final volume of 25 μ L.

Cycles for CCoV were as follows: *M* gene, 94°C/10min, followed by 35 cycles of 94°C/30sec, 55°C/1min 72°C/1min, followed by 72°C/10min for final extension. For both reaction for *S* gene (one for CCoV-I and another separated for CCoV-II): 94°C/5min, 35 cycles of 94°C/1min, 50°C/1min and 72°C/2min, followed by 72°C/10min; For *N* gene, 94°C/5min and 35 cycles of 95°C/1min, 53°C/40sec and 72°C/30sec, followed by

72°C/10min. For *3b* gene 94°C/10min, 35 cycles of 94°C/30sec, 55°C/1min e 72°C/1min, followed by 72°C/10min final extension

For CPV VP2 protein gene detection, the cycle was 94°C/10min, followed by 34 cycles of 94°C/30sec, 55°C/1min and 72°C/1min, followed by 72°C/10min for final extension of the gene encoding the.

A samples were considered if the correspondent amplicons for CCoV M and CPV VP-2 genes (Table 2 and 3) were detected after electrophoresis on 1.5% agarose gel stained with ethidium bromide at 0.5 μ g/mL and observed under ultra-violet light.

Table 2 - Primers used for amplification and partial sequencing of the genes encoding the M, S, N and 3b proteins of canine coronavirus.

Gene	Primers	Strand	Sequence (5'- 3'')	Amplicon size	References		
	CCV1	Forward	TCCAGATATGTAATGTTCGG	410.1	D + 11' + 1 (1000)		
М	CCV2	Reverse	TCTGTTGAGTAATCACCAGCT	410 bp	Pratelli et al. (1999)		
	EL1F	Forward	CAAGTTGACCGTCTTATTATTACTGGTAG	CCoV Type I			
S	EL1R	Reverse	TCATATACGTACCATTATAGCTGAAGA	346 bp	$D_{matalliates} = 1.0004$		
(3^)	S5	Forward	TGCATTTGTGTCTCAGACTT	CCoV type II	- Fiatelli et al., (2004),		
	S6	Reverse	CCAAGGCCATTTTACATAAG	694 bp			
N	CENP1	Forward	CTCGTGGYCGGAAGAATAAT	200 hm	Erles e Brownlie		
IN	CENP2		GCAACCCAGAMRACTCCATC	280 bp	(2009)		
2h	NSP3B-S	Forward	CTTGGTCTCTCTATTGTTGAAG	200 hr	This study		
30	NSP3B-A	Reverse	GCGTTGCGTTTAGAATGG	200 bp	This study		

Table 3 - Primers used for detection of VP2 of canine parvovirus.

Primers	Strand	Sequence (5' -3')	Amplicon size	Reference
555F	Forward	CAGGAAGATATCCAGAAGGA	583 pb	McElligott et al., 2011
555R	Reverse	GGTGCTAGTTGATATGTAATAAACA		

2.5. Statistical analysis

CCoV and CPV results data were registered on a calculation sheet and analyzed for vaccination and enteritis presence using Chi-square analysis in the IBM SPSS (Statistical Package for Social Sciences, 2012) version 20.

Amplicons of the *M*, *S*, *N* and *3b* genes of CCoV were purified from agarose gels with GFXTM PCR DNA and GEL BAND Purification KitTM (GE Healthcare) and submitted to bidirectional DNA sequencing using BigDye 3.1^{TM} (Applied Byosystems) and ABI-3500 Genetic AnalyzerTM (Applied Byosystems) as per manufacturer's instructions.

The chromatograms obtained for each DNA strand sequences of each sample were subjected to Phred application online (http://asparagin.cenargen.embrapa.br/phph/ to evaluate the quality of the same ones). Only positions with scores higher than 20 (less than 1 % of error probability) were used and the chromatograms were also manually checked with the program Finch TV [©] ([©]Geospiza) to search for interpretation errors and discrepancies between each DNA strand sequenced.

The CAP sequence assembly of each sequence was obtained with the program BioEdit version 7.2.5 and submitted to BLASTn (http://www.ncbi.nlm.nih.gov/BLAST).

2.7. Phylogenetic analysis

The final nucleotide and putative amino acids sequences *M*, *S*, *N* and *3b* genes of CCoV were aligned with homologous sequences of *Alphacoronavirus-1* retrieved from GenBank (accession numbers of common sequences at the phylogenetic analysis: DQ201447; GQ477367; KC175340; JQ404410; JQ404409; EU924790; AY342160; F682842; EU924791; EU856361; EU856362; HQ462571; GQ152141; NC_002306; DQ112226; in addition for *M*, *S* and *N*, but not for *3b* trees: D13096; DQ811789; DQ112226; and only for *M*: GU300113; GU300120; GU300129; GU300127; JX442376; JX442377; JX442378; JF682842; for *S*: JF682842; AY170345; KF312719; JX446572; for *N*: JF682842; for *3b*: JQ408980; AY426983), using CLUSTAL/W application running in BioEdit v. 7.2.5.

The alignments were used to build Neighbor-Joining (NJ) nucleotide (with the Maximum Composite Likelihood model) and amino acids (with the Poisson model) trees with 1000 bootstrap replicates using MEGA 6.0 (Tamura et al., 2013).

All sequences generated in this study were deposited in the GenBank under the accession numbers: KP322041 to KP322050 for *S* gene from CCoV-I; KP322051 to KP322053 for *S* gene from CCoV-II; KP322054 to KP322088 for *M* gene; KP322089 to KP322111 for *N* gene;

Though the 3b amplicon had an expected size of 200 bp, when the respective primers were exclude during sequence editing, sequences were below the minimum size for Genbank submission, but they are available upon request to the authors.

3. Results

Regarding CCoV, 40.17% (47/117) of the samples were positive for M gene (Table 1), with frequencies of positives being of 37.5% (27/71) and 44.45% (20/45) amongst animals with and without diarrhea, respectively, while 57.45% (27/47) of CCoV-positive animals showed enteritis. Most of the positive animals were younger than 3 months (36/47). CCoV was detected in 54.69% (35/64) of unvaccinated animals, 33.34% (2/6) of those with complete vaccine schedule, 100% (8/8) in those with incomplete vaccine schedule, and in 5.1% (2/39) in those animals for with no vaccination data was available.

Concerning CPV, 13.68% (16/117) of the total samples resulted positive by PCR, with frequencies of positives being of 19.45% (14/72) and 4.5% (2/45) amongst animals with and without enteritis, respectively; 37.5% (6/16) of the CPV-positive animals were co-infected with CCoV and 87.5% (14/16) had enteritis.

Chi-square tests using SPSS20.0 software comparing enteritis x CPV (p=0.02) and vaccine x CPV (p=0.01) was considered statistically significant. However, enteritis x vaccine (p=0.30), enteritis x CCoV (p = 0.45) and vaccine x CCoV (p = 0.25) were without statistical significance.

Only high-quality DNA sequences (Phred score> 20) were included for the analyses of M (n=35), S (n=10 for CCoV-I and 3 for CCoV-II), N (n=23) and 3b (n=27) genes.

Phylogenetic analysis for *M* gene showed that the strain of the positive control and eight strains from fecal samples were included in the same group of CCoV-II strains, and the other ones were included in CCoV-I group for both nt and aa trees (Fig. 1). The non-synonymous between CCoV types I and II in the amino acid alignment are located at positions: 150 (Val \rightarrow Ile/ Phe/ Thr), 154 (Ala \rightarrow Val / Ile), 200 (Thr \rightarrow Val), 220 (Met \rightarrow Ile), 227 (Glu \rightarrow Asp), 228 (His \rightarrow Asn) and 250 (Gln \rightarrow Lys) regarding *M* gene of the strain 1-71 (VR-809 ATCC) GenBank access number JQ404409 (Fig. 2). Amino acids substitutions in M of CCoV-I strains from te present study are also found in the FIPV USA strain, GenBank number NC002306, with 82.5% - 83.1% nt and 90% aa identities amongst them, while CCoV-II strains showed 77.7% - 78.5% nt and 82.7% - 83.6% aa identity with the FIPV strain.

In agreement to what was found for M gene trees, S gene phylogenetic analysis resulted in two major clusters, *i.e.*, one for CCoV type I and another one for CCoV type II strains (Fig. 3), with amino acids substitutions between types I and II (Fig. 4) at positions: 1161 (Ala \rightarrow Thr), 1166 (Tyr \rightarrow Phe), 1168 (Ala \rightarrow Ser), 1173 (Gln \rightarrow Arg), 1174 (Tyr \rightarrow Gln), 1175 (Thr \rightarrow Ala), 1178 (Lys \rightarrow Arg), 1185 (Met \rightarrow Lys), 1186 (Glu \rightarrow Asp), 1193 (Lys \rightarrow Arg), 1197 (Asp \rightarrow Gln), 1199 (Tyr \rightarrow Phe), 1217 (Asp \rightarrow Asn), 1219 (Leu \rightarrow Met), 1220 (Leu \rightarrow Ile), 1222 (Leu \rightarrow Phe), 1230 (Glu \rightarrow Ala), 1231 (Trp \rightarrow Tyr), 1232 (Glu \rightarrow Thr), 1242 (Val \rightarrow Ala), 1243 (Asn \rightarrow Leu/Ser), 1245 to 1247 (deletion of the three aa – Gly,

Asp and Arg), 1249 (Tyr \rightarrow Phe), 1250 (Ala \rightarrow Gly), 1251 (Tyr \rightarrow Leu), 1253 (Leu \rightarrow Val), 1256 (Phe \rightarrow Val), 1257 (Lys \rightarrow Gln), 1258 (Ser \rightarrow Leu), 1259 (Ser \rightarrow Thr) and 1260 (deletion) with reference *S* gene of the strain 1-71 (VR-809 ATCC) GenBank access number JQ404409 (Fig. 4). One Brazilian CCoV-I strain (KF312719), not from this study, showed the amino acid Arg at position 1178 instead of Lys. For *S* gene the identity amongst CCoV-I strains from this study and FIPV strain (NC_002306) were 65.5% for nt and 67.3% for aa. All the CCoV-I strains from this study had 100% nt and aa identities with each other, 96.5% nt and 100% amino acid identity with CCoV-I Elmo/02 strain (AY170345), 99.3% nt and 98.9% with a CCoV-I Brazilian strain from another study (GenBank Accession number KF312719). Regarding CCoV-II, TGEV and FCoV-II from GenBank (see Fig.s 3 and 4 for GenBank accession numbers) the identities ranged from 64.5% to 66.5% for nt and 65.3% to 67.3% for aa for *S*.

On the CCoV-II *S* gene tree (Fig. 5), CCoV-II/dog50 and CCoV-II/dog57 strains segregated in the same cluster with the Brazilian CCoV-IIa Cao4 strain (GenBank accession No. JX446572) also from Rio Grande do Sul State (Fig. 5). The identity ranged from 97.8% to 98% for nt and 99% to 99.5% for aa, respectively, among them and this other Brazilian strain. Taking into account the other alphacoronaviruses included in the analysis, there was 92.8% to 94.3% nt and 92.9% to 99% aa identity amongst CCoV-II and FIPV, and TGEV). Comparing the CCoV-II strains from this study and the CCoV-I Elmo/02 strain (AY170345), nt identities were 61.8% - 62.1% and, for aa, 57.5%.

In the trees for the N gene (nt and aa, Fig. 6), though a lower resolution was found when compared to M trees, two CCoV-II strains from this study (CCoV-II/dog50 and CCoV-II/dog 56) clustered with one CCoV-II (GenBank GQ477367), with 95.8% to 97% nt and 95% to 96.2% aa identities. All CCoV-I strains of this study segregated in a unique cluster and showed 93.3% to 100% nt and 95% to 98.7% aa identities among them. Amino acids

substitutions could also be noticed in the aa alignment of *N* gene (Fig. 7). For *N* gene the identities among CCoV-I strains from this study and FIPV strain (NC_002306) were 80.8% - 83.7% for nt and 81.2% - 83.7% for aa.

Finally, the phylogenetic trees for *3b* gene (Fig. 8), shows that, except for the strain CCoV-II dog50 from this study, which clustered in the CCoV II cluster, one CCoV- II (CCoVII/dog 56) and all CCoV-I strains segregated in a cluster containing CCoVs type I and one FCoV serotype II (GenBank, accession numbers AY170345 (Elmo/02 strain), AY426984 (23/03 strain), and DF-2 R3i (JQ408980), respectively). Amino acids substitutions for *3b* gene are shown in Fig. 8.

The strain used as positive control in this study showed 100% identity for nt and aa for M, S and 3b gene, 99.1% nt and 98.7% aa for N gene, in the alignments with the strain 1-71 and was included in the same cluster of this vaccine strain. Nucleotide and amino acid identities among CCoV strains sequenced in this study and two CCoV vaccines strains, TN-449 (VR-2068 ATCC; GenBanK access number) and 1-71(VR-809 ATCC; GenBank access number JQ404410), for partial regions of M, S, N and 3b genes are shown in Table 4.

Table 4 – Nucleotide and amino acid identity among CCoV strains sequenced in this study and two strains, TN-449 (VR-2068 ATCC; GenBanK access number) and 1-71(VR-809 ATCC; GenBank access number JQ404410), for partial regions of *M*, *S*, *N* and *3b* genes.

Gene (nt region for gene in the reference sequence)	Reference strain	Strains from this study	nt %	aa%
	TN 440	CCoV-I	88.2% - 89.1%	94.5%
	IN-449	CCoV-II	95.7% - 96.3%	98.1% - 99%
М		Positive Control	96.3%	96.3%
	1 71	CCoV-I	87.6% - 88.2%	92.7%
	1-/1	CCoV-II	95.7% - 96.9%	97.2% - 98.1%
		Positive Control	100%	99%
$S(CC_{o}V_{i})$	TN-449	CC _o V I	64.4%	67.3%
S (CC0V-I)	1-71		65.5%	67.3%
	TN 440	CCoV-II	92.9% - 94%	97.2% - 98.6%
a	11N-449	Positive Control	92.9%	97.6%
5	1.71	CCoV-II	91.4% - 92.5%	96.7% - 98.1%
	1-/1	Positive Control	100%	100%
		CCoV-I	84.5% - 87.5%	83.7% - 86.2%
	TN-449	CCoV-II	87.5% - 92.9%	87.5% - 92.5%
N		Positive Control	93.3%	91.2%
-		CCoV-I	85.4% - 88.3%	86.2% - 88.7%
	1-71	CCoV-II	87.5% - 94.1%	85% - 96.2%
		Positive Control	99.1%	98.7%
		CCoV-I	77% - 82.1%	73% - 78.8%
	TN 440	CCoV-II	78.3% - 87.8%	76.9% - 86.5%
	11N-449	CCoV dog 51	81.5%	78.8%
26		Positive Control	91%	88.4%
50		CCoV-I	79.6% - 82.1%	76.9% - 80.7%
	1 71	CCoV-II	81.5% - 91.7%	80.7% - 88.4%
	1-/1	CCoV dog 51	83.4%	82.6%
		Positive Control	100%	100%

Sample	Collection	State	Age	Sex	Breed	Enteritis	Vaccine	CCoV Corro M	CPV
<u> </u>	2010	PE	NI	NI	NI	Present	NI	Neg	Neg
2	2010	PE	NI	NI	NI	Present	NI	Neg	Neg
	2010	PE	NI	NI	NI	Present	NI	Neg	Neg
	2010	MT	2m	M	Dit Bull	Dresent		Neg	Bog
	-	MT	2.111	E	ND	Dresent		Neg	F US
	-	MT	2111	<u>г</u>	ND D' 1	Present	INI	N	Neg
6	-	MT	3m	F	Pinscher	Present	NI	Neg	Neg
7	-	MT	3m	Μ	Pinscher	Present	NI	Neg	Pos
8	-	MT	2m	F	Pinscher	Present	NI	Neg	Neg
9	-	MT	3m	F	Pit Bull	Present	NI	Neg	Neg
10	-	MT	2m	М	Rottweiler	Present	NI	Neg	Neg
11	-	MT	3m	F	Poodle	Present	NI	Neg	Neg
12	-	MT	3m	М	Pit Bull	Present	NI	Neg	Pos
13	-	MT	1m18d	F	Pit Bull	Present	NI	Neg	Pos
14	-	MT	1m	Μ	Rottweiler	Present	NI	Neg	Pos
15	-	MT	2m10d	F	NB	Present	NI	Neg	Pos
17	-	MT	3m	Μ	NB	Present	NI	Neg	Neg
18	-	MT	2m	F	NB	Present	NI	Neg	Neg
19	-	MT	3m	F	Pit Bull	Present	NI	Neg	Neg
21	-	MT	3m	Μ	Shi Tzu	Present	NI	Neg	Neg
23	-	MT	2m	F	NB	Present	NI	Neg	Neg
24	-	MT	2m21d	F	NB	Present	NI	Neg	Neg
25	-	MT	3m	Μ	NB	Present	NI	Neg	Neg
26	-	MT	2m	М	NB	Present	NI	Neg	Neg
27	-	MT	3m	F	NB	Present	NI	Neg	Pos
28	-	MT	4m	F	Dalmatian	Present	NI	Neg	Pos
29	-	MT	3m	F	Shar Pei	Present	NI	Neg	Pos
30	-	MT	2m	F	Shar Pei	Present	NI	Neg	Pos

Table 1 - Fecal samples from dogs collected in this study and results for PCRs detection of CCoV and CPV. (NI) not informed data; (PE) Pernambuco State; (MT) Mato Grosso State; (RS) Rio Grande do Sul State; (SP) Sao Paulo State; (m) months; (d) days; (F) Female; (M) male; (NB) No breed; (Neg) negative; (Pos) positive;

31	-	MT	4m	М	NB	Present	NI	Neg	Neg
32	-	MT	3m	F	NB	Present	NI	Neg	Neg
33	-	MT	2m	М	Bull Terrier	Present	NI	Neg	Neg
40	2011	SP	12m	М	Basset Hound	Absent	NI	Neg	Neg
41	2011	SP	5m	М	Lhasa Apso	Absent	NI	Neg	Neg
42	2009	RS	4m	М	Border Collie	Absent	Absent	Pos	Neg
43	2009	RS	2m	F	NB	Absent	Absent	Pos	Neg
44	2009	RS	2m	F	NB	Absent	Absent	Pos	Neg
45	2009	RS	2m	F	NB	Absent	Absent	Pos	Neg
46	2009	RS	5m	М	NB	Absent	Complete	Pos	Neg
47	2009	RS	5m	М	NB	Absent	Complete	Pos	Neg
48	2009	RS	2m	F	NB	Absent	Incomplete	Pos	Neg
49	2010	RS	2m	М	German Shepherd	Absent	Incomplete	Pos	Pos
50	2010	RS	2m 15d	F	Shi Tzu	Present	Incomplete	Pos	Pos
51	2009	RS	2m	F	NB	Absent	Absent	Pos	Neg
52	2010	RS	1m	М	Golden	Present	Incomplete	Pos	Pos
53	2008	RS	4m	М	Akita	Absent	Absent	Pos	Pos
54	2009	RS	7m	М	NB	Absent	Absent	Pos	Neg
55	2010	RS	6m	М	Pinscher	Present	Incomplete	Pos	Pos
56	2009	RS	3m	F	NB	Absent	Absent	Pos	Neg
57	2009	RS	3m	F	NB	Absent	Absent	Pos	Neg
58	2010	RS	3m	F	NB	Absent	Absent	Pos	Neg
59	2009	RS	2m	F	NB	Present	Absent	Pos	Pos
60	2012	SP	4m	F	Jack Russel	Present	Incomplete	Pos	Neg
61	2012	SP	2m	М	Pinscher	Absent	Absent	Neg	Neg
62	2012	SP	2m	М	Jack Russel	Present	Incomplete	Pos	Neg
63	2012	SP	2m	М	Jack Russel	Absent	Absent	Neg	Neg
64	2012	SP	12m	F	Bernese	Absent	Absent	Neg	Neg
65	2012	SP	3m	F	French Bulldog	Present	Absent	Pos	Neg
66	2012	SP	10m	F	Australian Sheppherd	Present	Absent	Neg	Neg

67	2012	SP	3m	М	Jack Russel	Present	Absent	Pos	Neg
68	2012	SP	25d	М	Pinscher	Absent	Absent	Neg	Neg
69	2012	SP	25d	М	Pinscher	Absent	Absent	Neg	Neg
70	2012	SP	25d	F	Pinscher	Absent	Absent	Neg	Neg
71	2012	SP	16d	F	Pinscher	Absent	Absent	Neg	Neg
72	2012	SP	3m	М	Jack Russel	Absent	Absent	Pos	Neg
73	2012	SP	2m	М	Pinscher	Present	Absent	Pos	Neg
74	2012	SP	2m	F	Lhasa Apso	Absent	Absent	Neg	Neg
75	2012	SP	3m	F	Jack Russel	Present	Absent	Pos	Neg
76	2012	SP	3m	F	Jack Russel	Present	Absent	Pos	Neg
77	2012	SP	12m	F	Pinscher	Present	Complete	Neg	Neg
78	2012	SP	4m	F	Italian Greyhouy	Present	Complete	Neg	Neg
79	2012	SP	4m	F	Italian Greyhouy	Present	Absent	Neg	Neg
80	2012	SP	9m	F	French Bulldog	Present	Absent	Pos	Neg
81	2012	SP	4m	М	Pinscher	Present	Absent	Pos	Neg
82	2012	SP	12m	М	Pug	Present	Absent	Neg	Neg
83	2012	SP	12m	F	Jack Russel	Absent	Complete	Neg	Neg
84	2012	SP	12m	F	Jack Russel	Absent	Complete	Neg	Neg
88	2012	SP	4m	М	Golden	Present	NI	Pos	Neg
89	2012	SP	2m	F	Yorkshire Terrier	Present	NI	Pos	Neg
90	2012	SP	50d	F	Yorkshire Terrier	Absent	Absent	Neg	Neg
91	2012	SP	50d	F	Yorkshire Terrier	Absent	Absent	Neg	Neg
92	2012	SP	45d	F	French Bulldog	Present	Absent	Pos	Neg
93	2012	SP	45d	F	French Bulldog	Present	Absent	Pos	Neg
94	2012	SP	45d	М	French Bulldog	Present	Absent	Pos	Neg
95	2012	SP	45d	М	French Bulldog	Present	Absent	Pos	Neg
96	2012	SP	45d	F	French Bulldog	Absent	Absent	Neg	Neg
97	2012	SP	45d	М	French Bulldog	Present	Absent	Pos	Neg
98	2012	SP	45d	М	French Bulldog	Present	Absent	Pos	Neg
99	2012	SP	40d	F	Pinscher	Present	Absent	Pos	Neg

100	2012	SP	40d	М	Pinscher	Absent	Absent	Pos	Neg
101	2012	SP	40d	М	Pinscher	Present	Absent	Pos	Neg
102	2012	SP	40d	F	Pinscher	Absent	Absent	Neg	Neg
103	2012	SP	40d	F	Pinscher	Absent	Absent	Neg	Neg
104	2012	SP	40d	F	Pinscher	Absent	Absent	Pos	Neg
105	2012	SP	40d	М	Pinscher	Present	Absent	Neg	Neg
106	2012	SP	50d	М	Lhasa Apso	Absent	Absent	Neg	Neg
107	2012	SP	50d	М	Lhasa Apso	Absent	Absent	Neg	Neg
108	2012	SP	50d	М	Lhasa Apso	Absent	Absent	Neg	Neg
109	2012	SP	50d	М	Lhasa Apso	Absent	Absent	Neg	Neg
110	2012	SP	37d	F	Golden	Absent	Absent	Neg	Neg
111	2012	SP	50d	F	Lhasa Apso	Absent	Absent	Neg	Neg
112	2012	SP	3m	М	Chihuahua	Present	Absent	Pos	Neg
113	2012	SP	8d	F	French Bulldog	Present	Absent	Pos	Neg
114	2012	SP	37d	М	Golden	Present	Absent	Pos	Neg
115	2012	SP	37d	М	Golden	Absent	Absent	Neg	Neg
116	2012	SP	37d	М	Golden	Absent	Absent	Pos	Neg
117	2012	SP	37d	F	Golden	Absent	Absent	Pos	Neg
118	2012	SP	37d	М	Golden	Absent	Absent	Pos	Neg
119	2012	SP	37d	М	Golden	Absent	Absent	Neg	Neg
120	2012	SP	2m	F	NB	Present	Absent	Neg	Neg
121	2012	SP	5m	F	Jack Russel	Present	Absent	Neg	Neg
122	2012	SP	3m	F	German Shepherd	Present	Absent	Neg	Neg
123	2012	SP	4m	М	NB	Present	Incomplete	Pos	Neg
124	2012	SP	NI	-	-	Present	NI	Neg	Neg
125	2012	SP	NI	-	-	Present	NI	Neg	Neg
126	2012	SP	6m	М	Yorkshire Terrier	Present	Absent	Neg	Neg
128	2012	SP	NI	-	-	Present	NI	Neg	Neg
131	2012	SP	5m	М	NB	Present	NI	Neg	Neg
132	2012	SP	2m	F	Spitz Alemão	Present	NI	Neg	Neg

Fig. 1. Phylogenetic trees for partial sequences of nt and as for M gene; strains from this study are in bold and with an arrow. Each node represents the values of 1000 bootstrap replicates and has been demonstrated only bootstrap values above 50%. The bar represents the number of substitutions per site.



Fig. 2	. Differences	in amino	acid alignmen	t of CCoV	<i>M</i> gene	(reference strain	1-71	(VR-809
ATCO	C), genbank J	Q404409)).					

	150		160	170	18	190		200	210	5	220		2	30 240	5	250	Î.
	1.			11	11	11		.1 .			.1 .	1					
JQ404409_1-71_CCOVIIa_VR-809AT	IV	TFIL	MIMYF	IRSIQLYRRT	KSWWSFNPET	NAILCVSALG	RSYVLPL	GV I	TGVTLTLLS	GNLYAEG	FKI A	GGMN	IDNL	KYVMVALPSR	TIVYTLV	GKK I	KASSATGW
KP322054_CCoV-II/dog44_BRAZIL	. I	v.		v													
KP322055_CCoV-II/dog45_BRAZIL	. I	v.		v													
KP322056_CCoV-II/dog46_BRAZIL	. I	v.		v													
KP322057_CCoV-II/dog47_BRAZIL	. I	v.		v	· · · · · · · · · · · · · · ·	•••••				· · · · · · · · ·							
KP322058_CCoV-I/dog48_BRAZIL	VI	A.		v				. Т.			.м.		.EH			Q .	
KP322059_CCoV-II/dog50_BRAZIL	. I	v.		v													
KP322060_CCoV-II/dog55_BRAZIL	. I	v.		v						H							
KP322061_CCoV-II/dog56_BRAZIL	. I	v.		V													
KP322062_CCoV-II/dog57_BRAZIL	. I	v.		v													
KP322063_CCoV-I/dog60_BRAZIL	VI	A.		V				. Т.			.м.		.EH.			Q.	
KP322064_CCoV-I/dog62_BRAZIL	VI	A.	• • • • •	v		• • • • • • • • • • • •	••••	. Т.			. м.		.EH.			Q.	
KP322065_CCoV-I/dog65_BRAZIL	VI	A.		v			•••••	. Т.			. м.		.EH.	<mark>.</mark>		Q.	
KP322066_CCoV-I/dog67_BRAZIL	VI	A.		v				. Т.			M .		.EH.			. Q.	
KP322067_CCoV-I/dog72_BRAZIL	VI	A.		v				. Т.			.м.		.EH.			. Q .	
KP322068_CCoV-I/dog73_BRAZIL	VI	A.		v		· · · · · · · · · · · · · · · ·		. Т.			.м.		.EH.			Q .	
KP322069_CCoV-I/dog75_BRAZIL	VI	A.		V				. Т.			.м.		.EH.			. Q .	
KP322070_CCoV-I/dog76_BRAZIL	VI	A.		v	· · · · · · · · · · · · · · ·			. Т.			.м.		.EH.			Q.	
KP322071_CCoV-I/dog80_BRAZIL	VI	A.		v				. Т.			. м.		.EH.			Q.	
KP322072_CCoV-I/dog81_BRAZIL	VI	A.		v	· · · · · · · · · · · ·		<mark>.</mark>	Т			. м.		.EH.			Q.	
KP322073_CCoV-I/dog89_BRAZIL	VI	A.		v				. Т.			. М.		.EH			0 .	
KP322074_CCoV-I/dog92_BRAZIL	VI	A.		v				. Т.			. м.		.EH.			Q.	
KP322075_CCoV-I/dog93_BRAZIL	VI	A.		v				. Т.			. м.		.EH.			Q.	
KP322076_CCoV-I/dog94_BRAZIL	VI	A.		v				. Т.			.м.		.EH.			Q.	
KP322077_CCoV-I/dog95_BRAZIL	VI	A.		V		· · · · · · · · · · · · ·		T .			. м.	••••	.EH.			Q.	
KP322078_CCoV-I/dog97_BRAZIL	VI	A.		V				. Т.			. м.		.EH.			Q.	
KP322079_CCoV-I/dog98_BRAZIL	VI	A.	• • • • •	v				. Т.			. м.	• • • •	.EH.			Q.	
KP322080_CCoV-I/dog99_BRAZIL	VI	A.		V				. Т.			. м.		.EH.			Q.	
KP322081_CCoV-I/dog100_BRAZIL	VI	A.	• • • • •	v				Т.			. м.		.EH.			Q.	
KP322082_CCoV-I/dog101_BRAZIL	VI	A.		v		· · · · · · · · · · · · ·	• • • • • • • •	. Т.			. м.		.EH	• • • • • • • • • • • • • •		Q.	
KP322083_CCoV-I/dog112_BRAZIL	VI	A.	• • • • •	v				Т.			. м.		.EH			Q.	
KP322084_CCoV-I/dog114_BRAZIL	VI	A.		v				. Т			. м.		.EH			Q .	
KP322085_CCoV-I/dog116_BRAZIL	VI	A.		v				Т.	•••••		. м.		.EH.	• • • • • • • • • • • • •		· .Q .	
KP322086_CCoV-I/dog118_BRAZIL	VI	A.		v		•••••		. Т			. м.		.EH.			Q.	
KP322087_CCoV-I/dog123_BRAZIL	VI	A.		v	· · · · · · · · · · · ·			Т	•••••		. м.		.EH.	•••••		· .Q .	
KP322088_CCoV-II/VACCINE_BRAZI								•••	•••••		••• •					••••	
GU300113_Pt6_CCOVI_SP_BRAZIL	VI	A.		v				Т	•••••		. м.		.EH.			Q.	
GU300120_Sha_CCOVI_SP_BRAZIL	VI	A.	• • • • •	v				. Т.			. м.		.EH.			Q.	
GU300129_Tb2_CCOVII_SP_BRAZIL	• •	v.	• • • • •	v				• • • •	•••••		••••		• • • • •			••••	
GU300127_Pt8_CCOVII_SP_BRAZIL	. I	v.	• • • • •	v			.N	••••	•••••		••••	• • • •				· ·Q ·	
JX442376_isolate_cao2_CCOVIIa_	. I	v.	• • • • •	V			.N	• • • •	•••••		• • • •		• • • •			· · Q ·	C
JX442377_isolate_cao4_CCOVIIa_	· 1	v.	• • • • •	v			•••••	•••	•••••		• • • •	• • • •	•••••			• • • •	
JX442378_isolate_cao5_CCOVIIa_	P I	v.	• • • • •	v				• • • •	•••••		• • • •		• • • •			• • • •	
JF682842_NA/09_CCOVII_GREECE		••••	• • • • •	v				•••	•••••		• • • •	••••	••••			••••	
GQ477367_NTU336/F/2008_CCOV11_	• •		• • • • •	v				•••	•••••		• • •	• • • •				• • • •	
KC175340_K378_CCOVIIa_USA	1 : 2		••••					••• •	•••••		••• •	• • • •	• • • • •				
JQ404410_IN-449_CCOVIIa_VR2068	• 1	.v.		V				•••	•••••		• • • •					· · Q ·	
EU924790_430707_CCOVIIB_ITALY	• •			V	•••••			• • • •	•••••	•••••	••••	••••					
AY342160_BGF10_CCOVIIA_UK				V				• • • •	•••••		••• •		••••			u .	
DI3096_INSAVC-1_CCOVIIA_UK	т.			V		5		••••	•••••	····C···	••••	••••		v.		••••	
EU924/91_119/08_CCOVIID_ITALI	• •		• • • • •	V				••••	•••••		••••					••••	
EU856361_341/US_COUVII_IIALY	• •		• • • • •	V				• • • •			••• •		• • • • •			••••	
DODOLAAT TO TOPU CHINE	•••			V							••••					••••	
UQ20144/_IS_IGEV_CHINA	•		••••	V				J			• • • •	••••	••••			••••	
CO152141 NTH156/D/2007 FOULTA		· · · ·		V		A		•••			M	1 7	PH	т.т			
NC 002306 FIDU USA	v.			V V		N					. 12 . M	1.0	PH.	тт			
DOS11780 TOFU HINNIADE Durder	v .	. A.		vv		·····N····					11 .	· · ьТ	. па.			· · · · ·	
DO112226 CB/05 CCOVITA TTATY				v								••••				••••	
DATTERED_CD/03_CCOALTE_IIADI			1	******				•••			•••		••••			••••	

Fig. 3. Phylogenetic trees for partial nt and aa sequences of S gene comparing CCoV-I with CCoV-II; strains from this study are in bold and with an arrow. Each node represents the values of 1000 bootstrap replicates and has been demonstrated only bootstrap values above 50%. The bar represents the number of substitutions per site.



Fig. 4. Differences in amino acid alignment of CCoV S gene (reference strain 1-71 (VR-809 ATCC), genbank JQ404409).

	1160	1170	11	119	0	120	0 1210	0 122	12	30 1240	125	1260
	1.20					· · · I					· · · · I · · · · I	····I····I
JQ404409_1-71_CCOVIIa_VR-809AT	. т.	F.S	ROAR	KD	R	Q.F.		N.MI	.F	A Y.T	.AS.GDR.FG	L.V VOLTL
KP322041_CCoV-I/dog75_brazil	L AAI	NAYVAOT	LTOYTEVICAS	ROLAMERVNE	CVKSQS	DRYG	FCGNGTHLFS	LANAAPDGLL	PLHTVLLPTI	WEEVTAWSGI	CVNDTYA	YVLKDFKSS-
KP322042_CCoV-I/dog76_BRAZIL												
KP322043_CCoV-I/dog80_BRAZIL												
KP322044_CCoV-I/dog92_BRAZIL												
KP322045_CCoV-I/dog93_BRAZIL												
KP322046 CCoV-I/dog97 BRAZIL												
KP322047 CCoV-I/dog98 BRAZIL												
KP322048 CCoV-I/dog114 BRAZIL												
KP322049_CCoV-I/dog116_BRAZIL												
KP322050_CCoV-I/dog118_BRAZIL												
KF312719_891-I_CCOVI_BRAZIL			R									
AY170345_Elmo/02_CCOVI_ITALY												
DQ201447_TS_TGEV_CHINA	. Т.	F.S	ROA	KD	R	Q.F.		VN.MI	.F	Y.T A	.AL.GDR.FG	L.V VOLTL
HQ462571_WH-1_TGEV_CHINA	. т.	F.S	ROA	KD	R	Q.F.		N.MI	.F	Y.TP	.AS.GDR.FG	L.V VOLTL
GQ152141_NTU156/P/2007_FCOV_TA	. Т.,	F.S	ROA	KD	R	Q.F.		N.MI	.F	A Y.T	.AS.GDR.FG	L.V VOLTL
NC_002306_FIPV_USA	. т.	F.S	ROAR	KD	R	Q.F.		N.MI	.F	Y.T	.AS.GDR.FG	L.V VOLTL
DQ811789_TGEV_virulent_Purdue_	. T.	F.S	ROAR	KD	R	Q.F.		N.MI	.F	Y.T A	.AS.GDR.FG	L.V VOLTL
DQ112226 CB/05 CCOVIIa ITALY	. T.	F.S	ROAR	KD	R	Q.F.		N.MI	.F	Y.T	.AS.GDR.FG	L.V VOLTL
JF682842 NA/09 CCOVII GREECE	. т.	F.S	ROAR	KD	R	Q.F.		N.MI	.F	Y.T	.AS.GDR.FG	L.V VOLTL
GQ477367_NTU336/F/2008_CCOVII_	. т.,	F.S	ROA	KD	R	Q.F.		N.MI	.F.S	Y.T	.AS.GDR.FG	L.V VOLTL
KC175340 K378 CCOVIIa USA	. т.	F.S	ROAR	KD	R	Q.F.		N.MI	.F	Y.T	.AS.GDR.FG	L.V VOLTL
JQ404410 TN-449 CCOVIIa VR2068	. T.	F.S	ROA R	KD	R.	Q.F.		N.MI	.F	Y.T	.AS.GDR.FG	L.V VOLTL
EU924790 430/07 CCOVIIB ITALY	. T.	F.S	ROAR	KD	R	Q.F.		N.MI	.F	Y.T	AS.GDR.FG	L.V VOLTL
AY342160 BGF10 CCOVIIa UK	. т.	F.S	ROAR	KD	R	Q.F.		N.MI	.F	Y.T	AS.GNR.FG	L.V VOLTL
D13096 INSAVC-1 CCOVIIa UK	. Т.	F.S	ROAR	KD	R	Q.F.		N.MI	F	Y.T.	.AS.GSR.FG	L.VE.VOLTL
EU924791 119/08 CCOVIIb ITALY	. т.	F.S	ROAR	KD	R	Q.F.		N.MI	.F	Y.T	AS.GDR.FG	L.V VOLTL
EU856361 341/05 COOVII ITALY	. т	F.S	ROA R	KD	R	Q.F.		N.MI	.F	Y.T	AS.GDR.FG	L.V VOLTL
EU856362_174/06_COOVII_ITALY	. т.,	F.S	ROAR.	KD	R.	Q.F.		N.MI	.F	Y.T.	AS.GDR.FG	L.V VOLTL

Fig. 5. Phylogenetic tree for partial nt sequences of S gene for CCoV-II (with optimization criterion, NJ algorithm and evolutionary model MCL). Strains from this study are in bold and with an arrow. Each node represents the values of 1000 bootstrap replicates and has been demonstrated only bootstrap values above 50%. The bar represents the number of substitutions per site.



Fig. 6. Phylogenetic trees for partial sequences of nt and aa for N gene; strains from this study are in bold and with an arrow. Each node represents the values of 1000 bootstrap replicates and has been demonstrated only bootstrap values above 50%. The bar represents the number of substitutions per site.



Fig	. 7	. Differe	ences i	in amino	acid	alignment	of	CCoV	N gene	(reference	strain	1-71	(VR-8	309
AT	CC	C), genba	ank JQ	(404409)										

	30	40			50		60	70	ſ		80	Î		90			100)	
	1	••••			· · I					- 1			-1-	1		1			1
JQ404409_1-71_CCOVIIa_VR-809AT	Т	IPLSFFNPIT	100	GSKF	WNL	CPRDFV	PKGI	GNKDQQIGYW	NR	JSR	YRMVK	GOR	KEL	PERW	FFY	LGT	GPH	ADAK	FRORI
KP322089_CCoV-II/dog47_BRAZIL	D	•••••	.ĸ.	.A	.D.		.QK.		• •	.I.	• • • • •		.D.	• • • •	• • • •		• • •		I.OKL
KP322090_CCoV-II/dog50_BRAZIL		· · · · · · · · · · · · ·	• • •	• • • •	•••		• • • •		•••	.т.	• • • • •	• • •	•••	• • • •		•••	• • •		E
KP322091_CCoV-II/dog56_BRAZIL	D	•••••	.K.	• • • •					• •	.т.									
KP322092_CCoV-I/dog65_BRAZIL	D	• • • • • • • • • • • •	.K.	• • • •	.D.	• • • • • • •	.QK.		• •	Ι.		• • •	.D.	• • • •			•••		Q.L
KP322093_CCoV-I/dog67_BRAZIL	D	• • • • • • • • • • • •	.K.		.D.		.QK.		• •	Ι.			.D.						Q.L
KP322094_CCoV-I/dog72_BRAZIL	D	. 	.K.		.D.		.QK.		• •	Ι.			.D.						Q. L
KP322095_CCoV-I/dog73_BRAZIL	D		.K.		.D.		.QK.			Ι.			.D.						Q.L
KP322096_CCoV-I/dog75_BRAZIL	D	<mark></mark>	.K.		.D.		OK.			Ι.			.D.						Q.L
KP322097_CCoV-I/dog76_BRAZIL	D		.K.	· · · ·	.D.		OK.		• •	Ι.			.D.			· · · ·			Q.L
KP322098 CCoV-I/dog81 BRAZIL	D		.K.		.D.		OK.			Ι.			.D.			· · · ·			Q.L
KP322099 CCoV-I/dog92 BRAZIL	D		.K.		.D.		OK.			Ι.			.D.						Q.L
KP322100 CCoV-I/dog93 BRAZIL	D	<mark>.</mark>	.K.		.D.		. LK.		TL	Ι.			.D.			· · · ·			Q.L
KP322101 CCoV-I/dog94 BRAZIL	D	• • • • • • • • • • • •	.K.		.D.		OK.			Ι.			.D.						Q.L
KP322102 CCoV-I/dog95 BRAZIL	D	L	.K.		.D.		OK.			Ι.			.D.						Q.L
KP322103 CCoV-I/dog97 BRAZIL	D		.K.		.D.		OK.			.I.			.D.						L
KP322104 CCoV-I/dog98 BRAZIL	D	<mark>.</mark>	.K.		.D.		OK.			Ι.			.D.						Q.L
KP322105 CCoV-I/dog99 BRAZIL	D		.K.		.D.		OK.			Ι.			.D.						L
KP322106 CCoV-I/dog100 BRAZIL	D		.K.		.D.		OK.			Ι.			.D.					P.	L
KP322107 CCoV-I/dog101 BRAZIL	D		.K.		.D.		OK.			Ι.			.D.						L
KP322108 CCoV-I/dog114 BRAZIL	D		.K.		.D.		OK.			Ι.			.D.						L
KP322109 CCoV-I/dog116 BRAZIL	D		.K.		.D.		OK			Ι.			.D.						L
KP322110 CCoV-I/dog118 BRAZIL	D		.K.		.D.		OK			Τ.			.D.						. O. L
KP322111 CCoV-II/vaccine BRAZI																			
JE682842 NA/09 CCOVIT GREECE										T									
G0477367 NTU336/F/2008 CCOVIT	N									T			MA						
KC175340 K378 CCOVITA USA																	•••		
TO404410 TN-449 CCOVITA VR2068	N	D		Δ						T									E1
FU924790 430/07 COVIE TTALY										T			••••				•••		KT.
AV342160 BGF10 CCOVITA UK	D	v	V	••••	D		LV		•••	т			D.				•••		OK1.
DI 3096 INSAVC-1 CCOUTTA UN	D		P	• • • •	D.				•••	T.		P	N	V			• • •		OFT
FII924791 119/08 CCOUTE ITALY	2		.в.	••••			••••		•••	Ψ.			. 14 .	·			•••		QKL
EU924751_115705_CCOVIID_11AL1			•••	• • • •	•••		••••		•••	-		•••	•••	••••		• • • •	•••		
EU856361_341/05_COUVIT_TIALI			•••	••••	•••		••••		•••		•••••	•••	•••	••••			•••		
DODO1447 TO TOPU CUIND	NT.	· · P · · · · · · ·	• • •	• • • •	•••				•••		• • • • •	•••				••••	•••		
DQ201447_15_IGEV_CHINA	N	•••••	• • •	• • • •	• • •		.R.	R	•••		• • • • •	•••		• • • •		• • • •	• • •		KL
HQ4625/1_WH-1_IGEV_CHINA	N				••••		••••	·	•••	т.		•••					•••		KL
GQ152141_NIU156/P/2007_FCOV_TA	-		VES	.т	v		••••		•••	.v.		•••		.D			•••		· · · K.
NC_UU23U6_FIPV_USA	D	· · · · · ¥ · · · ·	.E.	••••	•••	· · · · b.	••••		•••	.1.		•••		A	1		•••		K.
DQ811789_TGEV_virulent_Purdue_	N	• • • • • • • • • • • •	• • •	••••	• • •		• • • •	R	• • •	т.		• • •	• • •						KL
DQ112226_CB/05_CCOVIIa_ITALY										.т.									

Fig. 8. Phylogenetic trees for partial sequences of nt and aa for 3b gene; strains from this study are in bold and with an arrow. Each node represents the values of 1000 bootstrap replicates and has been demonstrated only bootstrap values above 50%. The bar represents the number of substitutions per site.



0.2

Fig. 9. Differences in amino acid alignment of CCoV *3b* gene (reference strain 1-71 (VR-809 ATCC), genbank JQ404409).

	20		30	40	1	2	50	8	60	
	· · · · · ·		1			• 1 •	1		[
JQ404409_1-71_CCOVIIa_VR-809AT	SIVIQUEDI	TVYKE	KAKFW	YKLPFETR-L	RII	KH	K	PKALS	VTKDA	KRDYRKT
CCOV-II/Dog50_BRAZIL	N.		<mark></mark> .	····-·		EQ.			IS	I
CCOV-II/Dog56_BRAZIL	N.	S.				NN.		T.	.V.RN	.KI
CCOV/Dog51_BRAZIL	N.	N.				.N		I.	.V.RK	.KI
CCOV-I/Dog67_BRAZIL	N.	S.				NN		T	.V.RN	.KI
CCOV-I/Dog72_BRAZIL	N.	S.				NN.		T	.V.RN	.KI
CCOV-I/Dog73_BRAZIL	N.	S.				NN.		T.	.V.RN	.KI
CCOV-I/Dog75_BRAZIL	N.	s.			· · ·	NN.		T	.V.RN	.KI
CCOV-I/Dog76_BRAZIL	IN.	N.				NN		T	.V.RN	.K I
CCOV-I/Dog81_BRAZIL	N.	N.				.N		I.	.V.RK	.K I
CCOV-I/Dog88_BRAZIL	N.	N.				.N		I.	.V.RK	.KI
CCOV-I/Dog89_BRAZIL	N.	S.		····-·		NN.		T	.V.RN	.K I
CCOV-I/Dog92 BRAZIL	N.	S.				NN.		T	.V.RN	.KI
CCOV-I/Dog93 BRAZIL	N.	K S.				NN.		T.	V.RN	.K I
CCOV-I/Dog94 BRAZIL	N.	s.				NN.		T	.V.RN	.K I
CCOV-I/Dog95 BRAZIL	N.	s.				NN.		Т	V.RN	.K I
CCOV-I/Dog97 BRAZIL	N.	s.				NN.		T.	.V.RN	.K I
CCOV-I/Dog98 BRAZIL	N.	S.				NN.		T	V.RN	.K I
CCOV-I/Dog99 BRAZIL	N.	s.				NN.		T	V.RN	.K I
CCOV-I/Dog100 BRAZIL	N.	s.				NN		T	V.RN	.K I
CCOV-I/Dog101 BRAZIL	N.	s.				NN.		T.	V.RN	.K I
CCOV-I/Dog104 BRAZIL	N.	s.		YG		NN.		T.	V.RN	.K I
CCOV-I/Dog114 BRAZIL	N.	s.				NN.		T.	V.RN	.K I
CCOV-I/Dog116 BRAZIL	N.	s.				NN		т	V.RN	.K I
CCOV-I/Dog117 BRAZIL	N.	s.				NN.		T.	V.RN	.K I
CCOV-I/Dog118 BRAZIL	N.	s.				NN.		T.	V.RN	.K I
CCOV-II/vaccine BRAZIL										
AY426983 Elmo/02 CCOVI ITALY	N.	N.	Y.			.N		т	V.RK	.KI
JF682842 NA/09 CCOVII GREECE						EO			AS	I
GQ477367 NTU336/F/2008 CCOVII								s.	v	
KC175340 K378 CCOVIIa USA										
J0404410 TN-449 CCOVIIa VR2068	N.		D		c				AV	A
EU924790 430/07 CCOVIIB ITALY						EO			AS	
AY342160 BGF10 CCOVIIa UK	-MIGGL	NTLS.	VIVSN	H-WNN, ANV	HH.	OOL	HVIV	OTOI	SART	ONY.PEF
EU924791 119/08 CCOVIID ITALY						EO			AS	I
EU856361 341/05 COOVIL ITALY						EO			AS	
EU856362 174/06 COOVII ITALY						EO			AL	
DO201447 TS TGEV CHINA	-MIGG.S-L	NTLS.	VIVSN	HSTVNN, ANV	HH.	.0	RVTV	OHON	SART	ONY. PEF
H0462571 WH-1 TGEV CHINA	-MIGGL	STLS.	VIVSN	HSTVNN, ANV	HH.	001	RVIV	OHON	SART	ONY. PEF
G0152141 NTU156/P/2007 FCOV TA	T. N.								v	
NC 002306 FIPV USA	S.				C		R		v	Т
JO408980 DF-2 R31 FCOVIT HUNGA	N	N				N		T	V.RK	K
AY426984 23/03 CCOVT TTALY	N	N				N		T	V. HK	K
					• • •					

4. Discussion

In this study, nucleotide and amino acids diversity was found for all CCoV genes studied. Phylogenetic analysis for M gene showed that CCoV-I and CCoV-II separated in different cluster. CCoV-I presented similar as substitutions as a FIPV strain, what is in agreement with results reported by Pratelli et al. (2002). However, for S gene, the same FIPV

strain was closer to CCoV-II strains than CCoV-I, probably because M is highly conserved due to its role on virion assembly (Arndt et al., 2010), in opposition to the spike protein, a target for neutralizing antibodies (Schultze et al., 1991) in which the variation of the amino acids between CCoV-I and CCoV-II can be up to 46% (Pratelli, 2006).

Difference between types I and II were clearly shown on the trees for *S* gene. The region used for typing CCoV-I strains from this study had different substitution for types of CCoVs. However, a wider part of this gene is still needed to survey for subtyping and more accurate amino acid markers.

For N gene trees, CCoV-I and CCoV-II a lower resolution was found when comparing to M analyses, probably because the N gene is a largely conserved region with little variability (Lai and Cavanagh 1997; Master, 2006), being associated with the complex of viral transcription and replication (Verheije et al., 2010), mainly considering the small portion on N studied herein.

In relation to phylogenetic trees for *3b* gene, stable markers could be found to differentiate types I and I of CCoV, also because of small fragment. Since this gene is conserved for CCoV-I strains and tropism may support the occurrence of mutations and deletions (Lorusso et al., 2008; Le Poder et al, 2013).

The efficacy of the immunity provided by vaccines can be controversial with different types or subtypes of CCoV (Pratelli et al. 2004; Pratelli, 2007; Decaro et al, 2011) and major envelope proteins as the spike proteins are determinant (Masters and Perlman, 2013). Thus, taking into account the relatively high diversity of nucleotides and amino acid among CCoV strains sequenced in this study and two CCoV vaccine strains, TN-449 (VR-2068 ATCC) and 1-71(VR-809 ATCC), one could speculate that a low crossed-protection is in curse among then Brazilian canine population with regard o CCoV infection and disease.
Conventionally, the most important canine enteric pathogen for veterinarian clinicians is CPV. However, the frequency of CCoV in this study was higher than CPV. Most CCoV positive samples from this study were CCoV-I and were from a commercial kennel from São Paulo State. Enteritis in this Kennel also was correlated with stress factors, animal agglomeration, dietary changes and different pathogens.

PCR positivity for CCoV indicates the presence of the etiologic agent, but not necessarily the disease. However, studies have shown that co-infection with other pathogens, as canine parvovirus, can exacerbate the symptoms and be fatal in some cases (Pratelli et al., 1999; Yesilbag et al., 2007). Besides, some CCoV strains can cause severe gastroenteritis and systemic disease, being fatal for puppies (Buonavoglia et al., 2006; Decaro et al., 2007; Zicola et al., 2012). In the present study, as 12.76% (6/47) of CCoV positive animals were also positive for CPV. It is worth noting that most of them (4/6) had clinical signs.

Hence, this work showed that CCoV infection is spread out among canine in Brazil, and more studies about the molecular diversity are necessary to predict the risk of infection, and perhaps an effective vaccine is needed. Nevertheless, Castro et al. (2010) found 52.2% (36/69) seronegative vaccinated dogs, indicating that immunizations to CCoV may not be effective, so preventive measures should be better evaluated due to viral spread and failure of CCoV vaccine.

Thus, isolation of Brazilian strains, cloning, sequencing analysis and comparison of mutations in wider portions of the genome, especially *S* gene, are important to understand selection and recombination between minor variants among different types of *Alphacoronavirus*-1 and are the issue of future publications by the authors.

5. Conclusion

The nucleocapsid gene of CCoV is highly conserved among types I and type II, with a lower tree resolution regarding trees based on the matrix and spike genes. Strains of types I and II show a low polymorphism for the 3b gene and no stable markers for type differentiation is found in the 3b area under analysis in this study.

Conflict of interest

None

Acknowledgmentss

We are grateful to FAPESP for the scholarship granted (#2010/19399-2) to the first author, to CNPq (grant # 301225/2013-3) for the financial support and to Prof. Dr. Alessandra M. M. G Castro for valuable knowledge of primer design. This research project is in accordance with ethical principles purposed by Bioethics Commission of the School of Veterinary Medicine and Animal Science of the University of São Paulo (protocol number # 2188/2011). The authors do not have any connection with commercial companies mentioned in this work.

References

Arndt, A.L., Larson, B.J., Hogue, B.G. 2010. A conserved domain in the Coronavirus Membrane protein tail is important for virus assembly. Journal of Virology, 84, 11418-11428.

Buonavoglia, C., Decaro, N., Martella, V., Elia, E., Campolo, M., Desario, C., Castagnaro,M., Tempesta, M. 2006. Canine coronavirus highly pathogenic for dogs. Emerging InfectiousDiseases, 12 (3), 492-494.

Castro, C.C., Johann, J.M., Finger, P.F., Nunes, C.F., Vargas, G. D'a., Fischer, G., Hübner, S.O. 2010. Canine coronavirus (CCoV) in dogs vaccinated and unvaccinated domiciliated in Pelotas, RS, Brazil. Ciências Agrárias, Londrina, 31 (4), 995-1000.

Castro, T.X., Garcia, R.C.N.C., Gonçalves, L.P.S., Costa, E.M., Marcello, G.C.G., Labarthe, N.V., Mendes-Almeida, F., 2013. Clinical, hematological, and biochemical findings in puppies with coronavirus and parvovirus enteritis. Can. Vet. J. 54, 885-888.

Costa, E.M., Castro, T.X., Bottino, F.O., Garcia, R.C.N.C., 2014. Molecular charactezation of canine coronavirus strains circulating in Brazil. Veterinary Microbiology. 168, 8-15.

Decaro, N., Martella, V., Elia, G., Campolo, M., Desario, C., Cirone, F., Tempesta, M., Buonavoglia, C. 2007. Molecular characterization of the virulent canine coronavirus CB/05 strain. Virus Research, 125, 54–60.

Decaro, N. Mari V, Campolo M, Lorusso A, Camero M, Elia G, Martella V, Cordioli P, Enjuanes L, Buonavoglia C. 2009. Recombinant canine coronaviruses related to transmissible gastroenteritis virus of Swine are circulating in dogs. Journal of Virology, 83 (3), 1532-1537.

Decaro, N., Mari, V., Elia, G.; Addie, D.D., Camero, M., Lucente, M.S., Martella, V., Buonavoglia, C. 2010. Recombinant canine coronaviruses in dogs, Europe. Emerg Infect Dis., 16 (1), 41-47.

Decaro, N., Mari, V., Sciarretta, R., Colao, V., Losurdo, M., Catella, C., Elia, G., Martella, V., Del Giudice, G., Buonavoglia, C. 2011. Immunogenicity and protective efficacy in dogs of an MF59TM-adjuvanted vaccine against recombinant canine/porcine coronavirus Vaccine, 29, 2018–2023.

Decaro, N., Pratelli, A., Tinelli, A., Martella, V., Camero, M., Buonavoglia, D., Tempesta, M., Caroli, A.M., Buonavoglia, C. 2004. Fecal Immunoglobulin A Antibodies in Dogs Infected or Vaccinated with Canine Coronavirus. Clinical and diagnostic laboratory immunology, jan, 102–105.

Evermann, J.F., Mc Keirman, A.J., Eugster, A.K., Solozano, R.F., Collins, J.K., Black, J.W., Kim, J.S. 1988. Update on canine coronavirus infections and interactions with other enteric pathogens of the dog. Compan. Anim. Pract.(Canine Pract.), 19 (2), 6-12.

Evermann, J.F., Abbott, J.R., Han, S. 2005. Canine coronavirus-associated puppy mortality without evidence of concurrent canine parvovirus infection. Journal of Veterinary Diagnostic Investigation, 17 (6), 610-614.

Gizzi, A.B.R., Oliveira, S.T., Leutenegger, C.M., Estrada, M., Kozemjakin, D.A., Stedile, R., Marcondes, M., Biondo, A.W., 2014. Presence of infectious agents and co-infections in diarrheic dogs determined with a real-time polymerase chain reaction-based panel. BMC Veterinary Reasearch. 10:23, 1-8.

Guirao, M.P., Souza, S.P., Jerez, J.A., Richtzenhain, L.J., Brandao, P.E., 2013. Phylogeny of canine coronavirus (CCoV) from Brazilian dogs based on membrane protein partial sequences. Arq. Bras. Med. Vet. Zootec. 65, 1887-1890.

ICTV-InternationalCommitteeonTaxonomyofViruses[http://ictvonline.org/virusTaxonomy.asp], accessed in January, 2015.

Lai, M. M. C., Cavanagh, D. 1997. The molecular biology of coronavirus. Advances in Virus Research, 48, 1-100.

Le Poder, S., Pham-Hung D'alexandry D'orangiani, Al, Duarte, L., Fournier, A, Horhogea, C, Pinhas, C, Vabret, A, Eloit, M. 2013. Infection of cats with atypical feline coronaviruses harbouring a truncated form of the canine type I non-structural ORF3 gene. Infect Genet Evol. Dec, 20, 488-494.

Lorusso, A, Decaro, N., Schellen, P., Rottier, P.J.M., Buonavoglia, C., Haijema, Bj, De Groot, R.J., 2008. Gain, Preservation, and Loss of a Group 1a Coronavirus Accessory Glycoprotein. J Virol.; 82 (20), 10312–10317.

Master, P.S. 2006. The molecular biology of coronaviruses. Advances in Virus Research, 66, 193-292.

Masters, P.S., Perlman, S., 2013 *Coronaviridae. In:* KNIPE, D.M.; HOWLEY, P.M.; Fields Virology, Lippincott Williams & Wilkins, Philadelphia, Pa. 1, 825-858.

McElligott, S., Collins, P. J., Sleator, R. D., Martella, V., Decaro, N., Buonavoglia, C., O'shea, H., 2011. Detection and genetic characterization of canine parvoviruses and coronaviruses in southern Ireland. Archives of Virology, 156, 495-503.

Mesquita, R.A., Anzai, E.K., Oliveira, R.N., Nunes, F.D. 2001. Avaliação de três métodos de extração de DNA de material parafinado para amplificação de DNA genômico pela técnica da PCR. Pesquisa Odontológica Brasileira, 15 (4), 314-319.

Ntafis, V., Mari, V., Danika, S., Fragkiadaki, E., Buonavoglia, C. 2010. An outbreak of canine coronavirus in puppies in a Greek Kennel. J Vet Diagn Invest, 22, 320-323.

Park, J.S., Choi, B.K., Vijayachandran, L.S., Ayyappan, V., Chong, C., Lee, K., Kim, S.C., Choi, C.W. 2007. Immunodetection of canine parvovirus (CPV) in clinical samples by polyclonal antisera against CPV-VP2 protein expressed in *Esherichia coli* as an antigen. Journal of Virological Methods, 146, 281-287.

Parrish, C. R., Aquadro, C. F., Strassheim, M. L., Evermann, J. F., Sgro, J.-Y.; Mohammed,H. O. 1991. Rapid antigenic-type replacement and DNA sequence evolution of canine parvovirus. Journal of Virology, 65 (12), 6544-6552.

Pinto, L.D., Barros, I.N., Budaszewski, R.F., Weber, M.N., Mata, H., Antunes, J.R., Boabaid, F.M., Wouters, A.T.B., Driemeier, D., Brandao, P.E., Canal, C.W., 2014

Characterization of pantropic canine coronavirus from Brazil. The Veterinary Journal. 202, 659-662.

Pratelli, A., Tempesta, M., Greco, G., Martella, V., Buonavoglia, C. 1999. Development of a nested PCR assay for the detection of canine coronavirus. Journal of Virological Methods, v. 80 (1), 11-15.

Pratelli, A., Martella, V., Elia, G., Decaro, N., Aliberti, A., Buonavoglia, D., Tempesta, M., Buonavoglia, C. 2001. Variation of the sequence in the gene encoding for transmembrane protein M of canine coronavirus (CCV). Mol. Cell Probes, 15, 229–233.

Pratelli, A., Elia, G., Martella, V., Tinelli, A., Decaro, N., Marsilio, F., Buonavoglia, D., Tempesta, M., Buonavoglia, C., 2002. M gene evolution of canine coronavirus in naturally infected dogs. Vet. Rec., 151, 758–761.

Pratelli,A.; Tinelli, A., Decaro, N., A; Martella ,V.; Camero, M.; Tempesta, M., Martini, M., Carmichael, L.E., Buonavoglia, C. 2004. Safety and efficacy of a modified-live canine coronavirus vaccine in dogs. Veterinary Microbiology, 99 , 43–49.

Pratelli, A. 2006. Genetic evolution of canine coronavirus and recent advances in prophylaxis. Veterinary Research, 37 (2), 191-200.

Pratelli, A. 2007. High-cell-passage canine coronavirus vaccine providing sterilising immunity Journal of Small Animal Practice, 48, 574–578.

Reed, A. P., Jones, E.V., Miller, T. J. 1998. Nucleotide sequence and genome organization of canine parvovirus. Journal of Virology, 62, 266-276.

Schultze, B., Gross, H.-J., Brossmer, R., Herrler, G., 1991. The S protein of bovine coronavirus is a hemagglutinin recognizing 9-*O*-acetylated sialic acid as a receptor determinant. Journal of Virology. 65, 6232-6237.

Soma, T., Ohinata, T., Ishii, H., Takahashi, T., Taharaguchi, S., Hara, M., 2011. Detection and genotyping of canine coronavirus RNA in diarrheic dogs in Japan. Research in Seterinary Science. 90, 205-207.

Tamura, K., Stecher, G., Peterson, D., Filipski, A., Kumar, S., 2013. MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0. Molecular Biology and Evolution, 30, 2725-2729.

Tupler, T., Levy, J.K., Sabshin, S.J., Tucker, S.J., Greiner, E.C., Leutenegger, C.M., 2012. Enteropathogens identified in dogs entering a Florida animal shelter with normal feces or diarrhea. Journal of the American Veterinary Medical Association, 241 (3), 338-343.

Verheije, M.H., Hagemeijer, M.C., Ulasli, M., Reggiori, F., Rottier, P.J.M., Masters, P.S., De Haan, C.A.M. 2010. The Coronavirus Nucleocapsid protein is dynamically associated with the replication-transcription complexes. Journal of Virology, 84 (21), 11575-11579.

Yesilbag, K., Yilmaz, Z., Ozkul, A., Pratelli, A., 2007. Aetiological role of viruses in puppies with diarrhoea. Vet Rec. 161, 169-70.

Zicola, A., Jolly, S., Mathijs, E., Ziant, D., Decaro, N., Mari, V., Thiry, E., 2012 Fatal outbreaks in dogs associated with pantropic canine coronavirus in France and Belgium. J Small Anim Pract. 53, 297-300.

II. Isolation of a putatively pantropic type II canine coronavirus strain in A72 cells

Barros, I.N.B. ^{1,2*}; Pinto, L.D.³; Silva, S.O.S. ¹; Filippsen, P. ¹; Menezes, W.B. ⁴; Sanches, A. A. ^{1,2}; Richtzenhain, L.J. ^{1,2}, Canal, C.W.³; Brandão, P.E. ^{1,2}.

¹Department of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine, University of São Paulo, Av. Prof. Dr. Orlando Marques de Paiva, 87, CEP 05508 270 - Cidade Universitária São Paulo/SP – Brasil; ²Coronavirus Research Group, University of São Paulo, Av. Prof. Dr. Orlando Marques de Paiva, 87, CEP 05508 270 - Cidade Universitária São Paulo/SP – Brazil; ³ Laboratory of Virology, School of Veterinary Medicine, University of Rio Grande do Sul, Brazil; ⁴ Department of Animal Science, Federal University of the Semi-Arid, Mossoró, Rio Grande do Norte, CEP 59625 900, Brazil.

*E-mail: cemavet@usp.br

ABSTRACT

Canine enteric coronavirus (CCoV) is an enveloped RNA virus causing gastroenteritis in dogs, with highly lethal strains reported. Two genotypes (CCoV type-I and CCoV type-II, with subtypes CCoV-IIa and CCoV-IIb) have been described, being CCoV-IIa considered a pantropic variant. Most studies focus on the molecular diversity of CCoV but only a few have described the isolation of this virus in cell culture, which is of most importance for phenotypical characterization and evolution studies. This study describes the isolation of a putatively pantropic canine coronavirus strain type II in A72 canine cells from a fecal sample from a dog, resulting in cytopathic effect on the 5th day of the 5th passage. Further cloning and sequence analysis are ongoing in order to understand the *in vitro* evolution and molecular epidemiology of canine coronavirus.

Keywords: Canine coronavirus; A72 cells; isolation.

1. Introduction

Canine coronavirus (CCoV) is a member of the order *Nidovirales*, family *Coronaviridae*, genus *Alphacoronavirus*, species *Alphacoronavirus-1*, together with transmissible gastroenteritis virus (TGEV) and feline coronavirus (FCoV) (Carstens, 2010). The genome of *Alphacoronavirus-1* is approximately 29kb (Dye and Siddell, 2008). CCoV is an enveloped virus with positive-stranded RNA usually responsible for gastrointestinal infection in dogs (Masters and Perlman, 2013), but in some cases this virus can cause systemic disease and outbreaks with high mortality in young dogs (Evermann, et al. 2005; Buonavoglia et al. 2006).

CCoV has a genome consisting of genes encoding spike (*S*), nucleocapsid (*N*), membrane (*M*) and envelope (*E*) structural proteins and ORFs translated into non structural proteins, as replicase polyprotein (ORF1 - open read frame 1), 3a, 3b, 3c, 7a and 7b (Masters and Perlman, 2013). The *S* protein is the most polymorphic in coronaviruses (Bosch et al. 2003) and the main target of neutralizing antibodies (Schultze et.al. 1991).

Currently, two different genotypes of CCoV have been recognized, CCoV-I and CCoV-II. The former shares high similarity with FCoVs, and the latter has been considered a pantropic CCoV variant (Pratelli et al. 2004; Pratelli, 2006) for presenting tropism for the lungs, kidneys, liver, spleen and lymph nodes (Buonavoglia et al. 2006). CCoV-II is further divided in two subtypes, CCoV-IIa, associated with fatal diarrhea, and CCoV-II b, as a result of recombination event between CCoV-II and TGEV (Decaro et al. 2009, 2010).

Canine coronaviruses are spread worldwide. The first isolation of canine coronavirus was in 1971 during an outbreak of gastroenteritis in military dogs (Binn et al. 1974). CCoV has been reported in Australia, Italy, Turkish, U.S.A, United Kingdom, Greece, Ireland, Japan, France and Belgium (Naylor et al. 2001; Pratelli et al. 2004; Yesilbag et al. 2004; Evermann, et al. 2005; Erles and Brownlie, 2009; Ntafis et al. 2010; McEligott et al. 2011; Soma et al. 2011; Zicola et.al 2012), including only a few isolation reports (Buonavoglia et al. 2006; Ntafis et al. 2011).

In Brazil, studies of detection and molecular characterization of CCoV have been published (Guirao et al. 2013; Castro et al. 2013; Pinto et al. 2014; Costa et al. 2014; Gizzi et al. 2014). However, no isolation for this virus has been reported so far for strains from this country.

This manuscript reports the isolation of a putatively pantropic canine coronavirus strain (CCoV-IIa) from a fecal sample from a dog from Brazil, including the description of the molecular typing and the isolation protocol.

2. Materials and methods

2.1. Fecal samples and CCoV molecular typing

A total of thirteen fecal samples of puppies with gastroenteritis were used for virus isolation. Total RNA extraction was performed with TRIzol Reagent[™] (Life Technologies) following the manufacturer's instructions. PCR for M gene was carried out using primers described by Pratelli et al. (1999) and M-MLV Reverse Transcriptase[™] (Life Technologies) plus GoTaq (Promega) Green Master Mix as per manufacturers' instructions.

The amplicons(410 bp) were purified from agarose gels with GFX[™] PCR DNA and GEL BAND Purification KitTM (GE Healthcare), followed by sequencing reactions performed with BigDye 3.1TM (Applied Biosystems) according to the manufacturer's instructions, and subjected to bi-directional DNA sequencing in an ABI-3500[™] Genetic Analyzer (Applied Biosystems). Evaluation of the quality of chromatograms obtained for each DNA strand sequences performed using Phred application online was (http://asparagin.cenargen.embrapa.br/phph/). Only positions with scores higher than 20 (less than 1 % of error probability) were used and the chromatograms were also manually checked using the program Finch TV[©] (Geospiza) to search for interpretation errors and discrepancies between each DNA strand sequenced. The final sequence of each strain was obtained using Cap-Contig in the program Bioedit version 7.2.5 and submitted to BLASTn in http://www.ncbi.nlm.nih.gov/BLAST.

The sequences were then aligned with homologous sequences of *Alphacoronavirus* retrieved from GenBank (GU300112; GU300113; GU300114; GU300115; GU300116; GU300120; GU300121; GU300123; GU300125; GU300126; GU300127; GU300128; GU300129; GU300130; GU300132; GU300133; GU300134; EU924790; EU924791; DQ112226; AY342160; D13096; EU856361; EU856362; HQ462571; DQ201447; JF682842; NC_002306; GQ152141) using CLUSTAL/W application/algorithm running in Bioedit 7.2.5 and the alignment was used to build a Neighbor-Joining nucleotide distance tree with the Maximum Composite Likelihood model and 1000 bootstrap replicates using MEGA 6 (Tamura et al. 2013).

2.2. Virus isolation

Canine Fibroma (A72, ATCC CRL 1542) cell line was used for CCoV isolation. A72 cells and the CCV 1-71 CCoV strain (ATCC VR 809) used as positive control in this study were kindly provided by Biovet Laboratories, Brazil. Cells were propagated in Eagle's MEM supplemented with 10% fetal bovine serum (FBS) and 25mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid). Each fecal sample was homogenized (10%v/v) in Eagle's MEM with gentamicin (50mg/mL) and kept at 4°C for 12 hours.

Next, the suspensions were centrifuged at 5,000g for 15 minutes at 4°C. Supernatants were filtered through 0.45 μ m filters (MilliporeTM) and 1 ml of the filtrate was inoculated on partially (~70 per cent) confluent A72 cell cultures and incubated at 37°C / 1 hour.

In parallel, 1 ml of serum-free MEM (negative control) or 1 mL of CCV 1-71 strain (positive control, $10^{4.03}$ TCID₅₀/mL) diluted 1:10 in MEM medium without serum were inoculated in parallel flasks as negative and positive controls, respectively.

After one hour for virus attachment, the inocula (fecal suspensions and both negative and positive controls) were discarded from the monolayers and 7ml of Eagle's MEM supplemented with 2% FBS was added to each flask. Cells were daily observed with a microscope for cytopathic effect (CPE) for 5 days. After this observation period, the monolayers were frozen at -80 ° C. The inoculation process was repeated for a total of 10 serial passages. Same A72 cells passages were used to inoculate controls and fecal samples in order to avoid interference of cell senescence. The presence of CCoV in each passage was assessed using the PCR for the M gene as described above.

3. Results

Eight strains clustered with CCoV type I strains and were named CCoVI/dog followed by 48, 60, 62, 65, 67, 80 and 81 (GenBank accession numbers KP322058, KP322063,

KP322064, KP322065, KP322066, KP3220067, KP322071 and KP322072, respectively). Five strains clustered with CCoV type II, supposedly pantropic strains, and were named CCoVII/dog followed by 44, 45, 46, 47 and 50 (GenBank accession numbers KP322054, KP322055, KP322056, KP322057 and KP322059, respectively).

Only cells inoculated with CCoVII/dog50 strain and the positive control showed cytopathic effect, beginning on the fifth day post-inoculation of the fifth passage, consisting of syncytia (Fig. 1). No other strain showed any CPE. All ten passages of CCoVII/dog50 and of the positive control were subjected to screening for CCoV using RT-PCR target to *M* gene, resulting all positive, while the ten passages of the negative control caused no changes in the monolayers.

4. Discussion

A CCoV strain (CCoVII/dog50) typed as type II was successfully isolated in A72 cells, since cytopathic effects were detected on the 5th day post-inoculation of the 5th passage and all the 10 passages resulted positive for CCoV after PCR for the M gene. The lack of isolation of the other four CCoV-II strains may be due to insufficient amount of virus for infection and the presence of non-viable virions but with genetic material enough to be detected by PCR, since RT-PCR has been shown to be more sensitive than isolation in cell culture for coronavirus detection (Mahony and Richardson, 2005).

The possible presence of other viruses in the fecal samples that might be competitors for replication factors might also inhibit the replication of CCoV (Condit, 2013).

The success on isolating CCoV-II and not CCoV-I can be explained by differences on the binding affinity of these viruses to cell receptors. It is known that spike protein is the major target for neutralizing antibodies (Schultze et al. 1991) and the most common component of the receptor for *S* gene in the surface of permissive cells membranes is sialic acids, which might act also as a receptor on susceptible cell cultures (Schultze and Herrler, 1992).

In a review, Cavanagh (2005) suggests that the binding of coronaviruses might occur by as synergic effect of two different receptors. The first receptor (a sialic acid) brings the virus and cell membranes closer, and the second receptor (e.g. aminopeptidase N, APN) is responsible for the membrane fusion (Schwegmann-Wessels et al. 2002). However, some receptors might carry out both functions for some coronaviruses (Cavanagh, 2005).

There are a number of differences amongst APNs as receptor of coronavirus even in the same viral species, as *Alphacororavirus*-1, as a consequence of virus-host co-evolution. For example, the spike protein of FCoV-II (Feline infectious peritonitis virus type II (FIPV-II) and feline enteric coronavirus type II (FECV-II)) has been derived from a recombination event between FCoV-I and CCoV-II (Herrewegh et al. 1998), while CCoV-I is genetically more similar to FCoV-I than to CCoV-II (Pratelli et al. 2003), leading to differences in the ability to bind to different APNs.

Hohdatsu et al. (1998) have shown that a monoclonal antibody to feline APN blocked the infection of primary feline cells by FCoV-II, CCoV and TGEV, showing that this is a receptor for FCoV type II but not for type I. This suggests that FCoV-II may be easier to isolate *in vitro* than FCoV-I, as well as CCoV-II when compared to CCoV-I, what can be used to explain the reason CCoV vaccines strains are all type II and the lack of success in isolating CCoV-I.

5. Conclusion

As a conclusion, a putatively pantropic canine coronavirus strain type II was isolated in canine cells causing a syncytial CPE, further supporting that CCoV type II is more readily isolated when compared to type I. Further cloning and sequence analysis are ongoing in order to understand the in vitro evolution and molecular epidemiology of canine coronavirus.

Conflict of interest

None

Acknowledgments

Financial support was provided by CNPq (grant # 301225/2013-3) and FAPESP (grant#2010/19399-2). This study was certificated by Bioethics Commission of the School of Veterinary Medicine and Animal Science of the University of São Paulo (protocol number # 2188/2011).

References

Binn, L., Lazar, E.C., Keenan, K.P., Huxsoll, D.L., Marchwicki, R.H., Strano, A.J., 1974.Recovery and characterization of a coronavirus from military dogs with diarrhea. Proc. Annu.Meet. U. S. Anim. Health Assoc. 78, 359–366.

Bosch, B.J., Van Der Zee, R., De Haan, C.A.M., Rottier, P.J.M, 2003. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. Journal of Virology. 77, 8801-8811.

Buonavoglia, C., Decaro, N., Martella, V., Elia, E., Campolo, M., Desario, C., Castagnaro,M., Tempesta, M., 2006. Canine coronavirus highly pathogenic for dogs. Emerging InfectiousDiseases.12, 492-494.

Cavanagh, D., 2005. *Coronaviridae*: a review of coronaviruses and toroviruses. In: Schmidt A and Wolff MH (eds.) Coronaviruses with Special Emphasis on First Insights Concerning SARS. Basel: Birkhäuser, 1-54.

Carstens, E.B., 2010. Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2009). Archives of Virology. 155, 133–146.

Castro, T.X., Garcia, R.C.N.C., Gonçalves, L.P.S., Costa, E.M., Marcello, G.C.G., Labarthe, N.V., Mendes-Almeida, F., 2013. Clinical, hematological, and biochemical findings in puppies with coronavirus and parvovirus enteritis. Can. Vet. J. 54, 885-888.

Condit, R.C., 2013. Principles of Virology. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott, Williams & Wilkins.1, 21-51.

Costa, E.M., Castro, T.X., Bottino, F.O., Garcia, R.C.N.C., 2014. Molecular charactezation of canine coronavirus strains circulating in Brazil. Veterinary Microbiology. 168, 8-15.

Decaro N., Mari V., Campolo M., Lorusso A., Camero M., Elia G., Martella V., Cordioli P., Enjuanes L., Buonavoglia C., 2009. Recombinant canine coronaviruses related to transmissible gastroenteritis virus of Swine are circulating in dogs. Journal of Virology. 83, . 1532-1537.

Decaro, N., Mari, V., Elia, G., Addie, D.D., Camero, M., Lucente, M.S., Martella, V., Buonavoglia, C., 2010. Recombinant canine coronaviruses in dogs, Europe. Emerg Infect Dis. 16, 41-47.

Dye, C., Siddell, S.G. 2005. Genomic RNA sequence of *Feline coronavirus* strain FIPV WSU-79/1146 Journal of General Virology 86, 2249-2253.

Erles, K., Brownlie, J., 2009. Sequence analysis of divergent canine coronavirus strains present in a UK dog population. Virus Research. 141, 21-25.

Evermann, J.F., Abbott, J.R., Han, S., 2005. Canine coronavirus-associated puppy mortality without evidence of concurrent canine parvovirus infection. Journal of Veterinary Diagnostic Investigation. 17, 610-614.

Gizzi, A.B.R., Oliveira, S.T., Leutenegger, C.M., Estrada, M., Kozemjakin, D.A., Stedile, R., Marcondes, M., Biondo, A.W., 2014. Presence of infectious agents and co-infections in diarrheic dogs determined with a real-time polymerase chain reaction-based panel. BMC Veterinary Reasearch. 10:23, 1-8.

Guirao, M.P., Souza, S.P., Jerez, J.A., Richtzenhain, L.J., Brandao, P.E., 2013. Phylogeny of canine coronavirus (CCoV) from Brazilian dogs based on membrane protein partial sequences. Arq. Bras. Med. Vet. Zootec. 65, 1887-1890.

Herrewegh, A.A.P.M., Smeenk, I., Horzinek, M.C., Rottier, P.J.M., Degroot, R J., 1998. Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. Journal of Virology. 72, 4508– 4514.

Hohdatsu, T., Izumiya, Y., Yokoyama, Y., Kida, K., Koyama, H., 1998. Differences in virus receptor for type I and type II feline infectious peritonitis virus. Archives of Virology. 143, 839–850.

Mahony, J.B., Susan Richardson, S., 2005. Molecular Diagnosis of Severe Acute Respiratory Syndrome. Journal of Molecular Diagnostics. 7, 5.

Masters, P.S., Perlman, S., 2013 *Coronaviridae. In:* KNIPE, D.M.; HOWLEY, P.M.; Fields Virology, Lippincott Williams & Wilkins, Philadelphia, Pa. 1, 825-858.

Mcelligott, S., Collins, P. J., Sleator, R. D., Martella, V., Decaro, N., Buonavoglia, C., O'shea, H., 2011. Detection and genetic characterization of canine parvoviruses and coronaviruses in southern Ireland. Archives of Virology. 156, 495-503.

Naylor, M.J., Monckton, R.P., Lehrbach, P.R., Deane, E.M., 2001. Canine coronavirus in Australian dogs. Aust. Vet. J.79, 116-119.

Ntafis, V., Mari, V., Danika, S., Fragkiadaki, E., Buonavoglia, C., 2010. Na outbreak of canine coronavirus in puppies in a Greek Kennel. J Vet Diagn Invest. 22, 320-323.

Pinto, L.D., Barros, I.N., Budaszewski, R.F., Weber, M.N., Mata, H., Antunes, J.R., Boabaid, F.M., Wouters, A.T.B., Driemeier, D., Brandao, P.E., Canal, C.W., 2014 Characterization of pantropic canine coronavirus from Brazil. The Veterinary Journal. 202, 659-662.

Pratelli, A., Tempesta, M., Greco, G., Martella, V., Buonavoglia, C., 1999. Development of a nested PCR assay for the detection of canine coronavirus. Journal of Virological Methods, 80, 11-15.

Pratelli, A., Martella, V., Decaro, N., Tinelli, A., Camero, M., Cirone, F., Elia, G., Cavalli,
A., Corrente, M., Greco, G., Buonavoglia, D., Gentile, M., Tempesta, M., Buonavoglia C.,
2003. Genetic diversity of a canine coronavirus detected in pups with diarrhoea in Italy.
Journal of Virological Methods. 110, 9-17.

Pratelli, A., Decaro, N., Tinelli, A., Martella, V., Elia, G., Tempesta, M., Cirone, F., Buonavoglia, C., 2004. Two genototypes of canine coronavirus simultaneously detected in the fecal camples of dogs with diarrhea. Journal of Clinical Microbiology, 42, 1797-1799.

Pratelli, A., 2006. Genetic evolution of canine coronavirus and recent advances in prophylaxis. Veterinary Research. 37, 191-200.

Schultze, B., Gross, H.-J., Brossmer, R., Herrler, G., 1991. The S protein of bovine coronavirus is a hemagglutinin recognizing 9-*O*-acetylated sialic acid as a receptor determinant. Journal of Virology. 65, 6232-6237.

Schultze, B., Herrler, G., 1992. Bovine coronavirus uses N-acetyl-9-O-acetylneuraminic acid as a receptor determinant to initiate the infection of cultured cells. J Gen Virol. 73, 901–906.

Schwegmann-Wessels, C., Zimmer, G., Laude, H., Enjuanes, L., Herrler, G., 2002. Binding of transmissible gastroenteritis coronavirus to cell surface sialoglycoproteins. Journal of Virology. 76, 6037–6043.

Soma, T., Ohinata, T., Ishii, H., Takahashi, T., Taharaguchi, S., Hara, M., 2011. Detection and genotyping of canine coronavirus RNA in diarrheic dogs in Japan. Research in Seterinary Science. 90, 205-207.

Tamura, K., Stecher, G., Peterson, D., Filipski, A., Kumar, S., 2013. MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0. Molecular Biology and Evolution, 30, 2725-2729.

Yesilbag, K., Yilmaz, Z., Ozkul, A., Pratelli, A., 2007. Aetiological role of viruses in puppies with diarrhoea. Vet Rec. 161, 169-70.

Zicola, A., Jolly, S., Mathijs, E., Ziant, D., Decaro, N., Mari, V., Thiry, E., 2012 Fatal outbreaks in dogs associated with pantropic canine coronavirus in France and Belgium. J Small Anim Pract. 53, 297-300.



Fig. 1. **A72 cells, 5th day of the 5th viral passage**. **A**. Negative control; **B**. CCoV positive control (CCV 1-71 strain (ATCC VR 809)); **C**. CCoVII/dog50 strain; **3rd day of the 10th viral passage**. **D**. Negative control; **E**. CCoV positive control (CCV 1-71 strain (ATCC VR 809)); **F**. CCoVII/dog50 strain; cytopathic effects characterized by syncytia, rounding and cell death detected in B, C, E and F.

III. In vitro evolution of CCoV-II based on partial spike gene markers

Barros, I.N.B.^{1,2}, Silva, S.O.S.^{1,2}; Taniwaki, S.A.^{1,2}; Brandão, P.E.^{1,2}.

¹Department of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine, USP, Av. Prof. Dr. Orlando Marques de Paiva, 87, CEP 05508 270 - Cidade Universitária São Paulo/SP – Brasil; ²Coronavirus Research Group, USP, Av. Prof. Dr. Orlando Marques de Paiva, 87, CEP 05508 270 - Cidade Universitária São Paulo/SP – Brazil; E-mail: cemavet@usp.br

ABSTRACT

Coronaviruses (CoVs) have a large positive-strand nonsegmented RNA and due to the genetic complexity and high RNA recombination events, CoVs have high diversity. Those mutations may help viral evolution in new host, new genotypes emerging, tropism or increasing virulence of viruses, for example. As canine coronavirus (CCoV), feline coronavirus (FCoV) and transmissible gastroenteritis virus (TGEV), which are the same species *Alphacoronavirus-1*, emerged as a result of recombination events among them. Changes correlated with highly pathogenic strains are usually found in *S* protein, the main target of neutralizing antibodies and the most polymorphic protein in coronaviruses. This report aimed to deep study a strain 1-71 adapted in A72 cells and its passages by cloning and sequencing based on partial *S* gene for analyzing mutations events in vitro. Results showed nonsynonymous mutations, silent and three aa deletion in the subunit S2 of *S* gene, but in a low number and without a passage-association pattern. Thus, cell-adapted strains may be highly genetically stable after serial passages in a same cell line, accumulating mainly synonymous nucleotide substitutions in the spike gene due to a stable cell-host relationship.

However, only a portion of the gene was analyzed here. Further studies as cloning and sequencing different genes, isolation and evolution studies of a natural strain are needed to understand the recombination events affecting coronaviruses. Considering that any documentation of CCoV evolutionary processes may serve for better understanding of basic virology and data base for other coronaviruses.

Keywords: Canine coronavirus; adaptation; recombination; selection; variants; A72 cells

1. Introduction

Coronaviruses are enveloped, pleomorphic viruses, approximately 220nm in diameter, with positive-sense single-stranded nonsegmented RNA as a genome with 27-32kb in length (Masters And Perlman, 2013). The large RNA virus has high diversity mainly due to the genetic complexity and high RNA mutation events (Makino et.al., 1986; Decaro and Buonavoglia, 2008).

Canine coronavirus (CCoV), feline coronavirus (FCoV) and transmissible gastroenteritis virus (TGEV) are currently classified in the same species *Alphacoronavirus-1*, (*Nidovirales: Coronaviridae: Coronavirinae*) (Carstens, 2010) and evolutionary studies on *Alphacoronavirus-1* have demonstrated that CCoV, FVoV and TGEV emerged as a result of recombination events among each other (Pratelli et al., 2004; Pratelli et al., 2006; Decaro et al. 2009).

CCoV has a genome consisting of genes encoding spike (*S*), nucleocapsid (*N*), membrane (*M*) and envelope (*E*) structural proteins and ORFs translated into non structural proteins, as replicase polyprotein (ORF1 - open read frame 1), 3a, 3b, 3c, 7a and 7b (Masters And Perlman, 2013). The *S* protein is the main target of neutralizing antibodies and the most polymorphic protein in coronaviruses (Bosch et al., 2003). Recombination events in *S* gene have been shown in a high lethal emerged CCoV, the pantropic strains (Decaro et al., 2007). New virulent viruses usually emerge due a incomplete adaption to the host that can take long duration to stabilize (Truyen et al., 1995).

CCoV is of special interest as a model for virus molecular evolution as it occurs as two types (I and II) and as low and high virulence lineages (Pratelli et al, 2004; Buonavoglia et al. 2006). Type II is the basis for vaccine strains currently in use worldwide and produced in A72 cells; despite a high occurrence of CCoV-I is reported (Guirao et al, 2013). Furthermore, no data on the molecular diversity of the vaccine strains in successive passage cell cultures and the mechanism of molecular evolution of CoV in vitro is available.

The aim of this investigation was to assess the clonal diversity of a CCoV-II vaccine strain after serial passages in A-72 cells based on the molecular diversity of the spike gene and to gather insights on coronaviruses molecular evolution

2. Material and Methods

2.1. CCoV strain and cell line

CCoV 1-71 type II vaccine strain (ATCC VR 809) and canine fibroma A72 (ATCC CRL 1542) cell line were used for this study and were kindly provided by Biovet Laboratories, Brazil.

Cells were propagated in Eagle's MEM supplemented with 10% fetal bovine serum (FBS) and 25mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid).

2.2. Serial passages of CCoV

For the first passage, 1mL of CCV 1-71 strain ($10^{4.03}$ TCID₅₀/mL) diluted 1:10 (v/v) in MEM was inoculated in 25 cm² flasks containing partially (~70%) confluent A72 cells and incubated at 37°C / 1 hour for virus attachment. Next, the virus suspension was discarded and 7ml of Eagle's MEM supplemented with 2% FBS was added to the flask.

Cells were daily observed with a microscope for cytopathic effect (CPE) for five days. After this observation period, the monolayers were frozen at -80°C. Then, 1mL of the respective lower passage was used for the next following the same protocol described above up to the 9th passage.

For each passage, another 25 cm^2 with A72 was mock-infected (negative control) with MEM without virus under the same conditions described for virus inoculation.

2.3. RNA Extraction and RT-PCR

For the original CCoV 1-71 and each passage (CCoV and negative control), total RNA extraction was extracted with TRIzol ReagentTM (Life Technologies) following the manufacturer's instructions. cDNA was reserve transcribed using 3.5 μL of the extracted RNA denatured at 95°C for 5 minutes, and then added to the reverse transcription mix containing 1 x First Strand BufferTM (Life Technologies), 1 mM of each dNTP, 10 mM DTT, 50ng of Random PrimersTM (Life Technologies TM) 100U of M-MLV Reverse TranscriptaseTM (Life TechnologiesTM), DEPC-treated water to 10μL, performing and incubating at 37°C for 60 minutes.

Primers used for *S* gene PCR were S5 (Forward – 5^{-1} TGCATTTGTGTCTCAGACTT 3⁻) and S6 (Reverse – 5^{-1} CCAAGGCCATTTTACATAAG 3⁻) with amplification of 694 bp

(Pratelli et al., 2004) (nucleotides 3492 to 4185 of *S* gene in the reference strain 1-71 (VR-809 ATCC), genbank JQ404409)).

PCR was carried out with 6 ml of cDNA in a reaction mix containing 1 x High Fidelity PCR buffer TM (Life Technologies), 0.2 μ M of each dNTP, 2mM of MgSO₄, 0.2 μ M of each primer, 1U of Platinum Taq Polymerase High Fidelity TM (Life Technologies) and water DEDEPC-water to 50 μ L. PCR cycling conditions were 94 °C for 5 min then 10 cycles of 94°C for 30 sec, 58.5°C for 30sec, 68°C for 5 min, followed by 30 cycles of 94°C for 30 sec, 55.5°C for 30sec, 68°C for 5 min, followed by a final extension step at 68°C for 10 min.

2.4. DNA Cloning and Sequencing

The 694bp S gene amplicons were purified using ExoSAP-IT TM (Affymetrix) and the total DNA visually quantified with Low Mass DNA Ladder TM (Life Technologies) according to the manufacturer's instructions.

The purified amplicons was inserted into the plasmid vector pTZ57R / T^{TM} (InsTAclone), according to the insert: vector proportion of 3:1 according to the following formula: Insert Quantity (ng) = vector (ng) x insert size (bp) x 3 / array size (bp).

The ligation reaction was performed at 15°C for 16 hours and was followed by the addition of 5µL of ligation reaction to 100 µL of competent DH5 α *E. coli* cells grown in LB (Luria-Bertani) liquid medium and incubated on ice for 20 to 30 min. After a thermal shock (42°C / 2 min and ice / 2min), 900µL of LB medium without antibiotics was added to the reaction and incubated at 37°C / 150rpm / 1h30min.

The cells were then plated on solid LB medium containing 100 μ g/ml ampicillin, IPTG (5-bromo-4-chloro-3-indolyl- β -D-galactosidase) and X-Gal (isopropylthio- β -Dgalactoside) and incubated up to 16 hours at 37°C.

Individual white colonies, predicted to have inserts, were selected and subjected to a reaction PCR to confirm the insertion of an amplicon. using 12.5 μ L of GoTaq Green Master MixTM (Promega), 0.5 μ L of each primer target to the plasmid (M13F – forward 5⁻-GTTTTCCCAGTCACGAC-3⁻; and M13R – reverse 5⁻-CAGGAAACAGCTATGAC – 3⁻) and 11.5 μ L of DEPC water to a final volume of 25 μ L followed by cycles of 94°C / 5 min and 30 cycles of 94°C / 30 sec, 45°C / 30 sec and 72°C / 1 min and a final extension of 72°C / 5min.

A number of 10 clones of each passage and of the original virus confirmed as carrying the inserted amplicon were subjected to DNA sequencing with BigDye 3.1^{TM} (Applied Byosystems) and ABI-3500 Genetic AnalyzerTM (Applied Byosystems) as per manufacturer's instructions using primers M13F and M13R. Evaluation of the quality of chromatograms obtained for each DNA strand sequences was performed using Phred application online (http://asparagin.cenargen.embrapa.br/phph/) and manual checked using the program Finch TV [©] ([©]Geospiza) to search for interpretation errors and discrepancies between each DNA strand sequenced. The final sequence of each clone was obtained using Cap-Contig, with phred score >20, in the program Bioedit version 7.2.5 and submitted to BLASTn in http://www.ncbi.nlm.nih.gov/BLAST for homology checking.

2.5. Sequences Analysis

Sequences of clones of each passage and the original virus (*e.g.* intra-passage analysis) were aligned using Clustal/W in Bioedit version 7.2.5 and compared in terms of nucleotide and amino acids identities.

Identical sequences that predominated in the intra-passage comparison were herein named as the Master Sequence for that passage, while those in lower frequencies were named Mutants.

Next, the Mutants and Master Sequences for all passages and the original virus were aligned together including *Alphacoronavirus* homologous sequences retrieved from GenBank (JQ404409; JF682842; GQ477367; KC175340; JQ404410; EU924790; AY342160; D13096; EU924791; EU856361; EU856362; DQ201447; HQ462571; GQ152141; NC_002306; DQ811789; DQ112226) using CLUSTAL/W running in Bioedit 7.2.5.

All sequences generated in this study were deposited in the GenBank under the accession numbers: KP281485 to KP281596.

3. Results

A total of 112 viable DNA sequences were obtained to passages 1 to 9 and the original CCoV 1-71 strain and only 12 nucleotide mutations were found amongst these sequences, ranging from 0 to 3 per passage (Table 1) but in a passage-exclusive way.

From these mutations the total of point mutations eight were transitions, three were transversions and one deletion. Of these mutations: six were missense leading to amino acid mutations, especially in the central region; five were synonymous codon mutations and there was a deletion of 9 nt / 3aa at passage three, in position 3935-3943 of the alignment with clones sequences and the reference strain 1-71 (VR-809 ATCC, genbank JQ404409) The deletion were in a Mutant variant of the third passage, and was not found in any of the other clones.

Table 1. Nucleotide and putative amino acids mutations of the spike gene of CCoV stain 1-71 passaged in A72 cells. P- passage number (0 refers to the original virus); NC - number of clones sequenced per each passage; MU - number of mutations per passage regarding the Master Sequence. Numbers in cells of each mutation represent the number of occurrences of that specific mutation. Positions at *S* gene in the reference strain 1-71 (VR-809 ATCC), genbank JQ404409).

Р	SC	MU	A3519G Arg/Arg	T3813C Thr/ Thr	G3528T Glu/Asp	C3699T Thr/Thr	A4165C Thr/Thr	TTGATATTA 3935 to 3943 Deletion	T4155C Asn/Asn	T3803G Phe/Cys	A3817G Arg/Gly	G3868A Cys/Tyr	G3875A Glu/Lys	A3527G Glu/Gly
								(ne+Asp+ne)						
0	9	2	1	1	0	0	0	0	0	0	0	0	0	0
1	10	3	0	0	1	1	1	0	0	0	0	0	0	0
2	11	0	0	0	0	0	0	0	0	0	0	0	0	0
3	11	2	0	0	0	0	0	1	1	0	0	0	0	0
4	10	1	0	0	0	0	0	0	0	1	0	0	0	0
5	13	1	0	0	0	0	0	0	0	0	1	0	0	0
6	13	2	0	0	0	0	0	0	0	0	0	1	1	0
7	12	0	0	0	0	0	0	0	0	0	0	0	0	0
8	11	0	0	0	0	0	0	0	0	0	0	0	0	0
9	12	1	0	0	0	0	0	0	0	0	0	0	0	1

Fig. 1. Mutations in amino acid of clones from this study and CCoV-II S protein at position 1172 to 1388 in reference to strain 1-71 (VR-809 ATCC Genbank JQ404409).

	118	0 1190	1200		0 1220	1230	2 124	10 125	0 126	1270		1
TO404409 1-71 CCOVITA VR-809AT	TROAEVRAS	BOLAKOKUNE	CVRSOSOREG	FCGNGTHLES	LANAAPNOMT	FEHTVLLPTA	VETVTAWSGT	CASDGDRTEG	LVVKDVDLTL.	FRNLDDKEYL	TPRTMYOPRV	A
TE682842 NA/09 CCOUTT CREECE												
CO477367 NTU336/F/2008 CCOVIT						5				G		-
KC175240 K278 CCOULTS USA											· · · · · · · · · · · · · · ·	
TO404410 TN-449 CCOULTS VD2068										· · · · · · · · · · · · · · · · · · ·		17
FU924790 420/07 CCOUTTE TTALY												
NY242160 BCE10 CCOULTA UN								N				
DI2096 INSNUC-1 CCOUITA UN												
FUS24781 118 (08 CCOUTTE TTNLY					•••••							-
EUSEGOCI 241/05 COOUTT TTALY												
FURE COCUTT TALY	•••••		• • • • • • • • • • •									
DOSOLAAR TE TOPU CUIN												
HOAGEERI WH-1 TOPU CHINA					· · · · · · · · · · · · · · ·			· · · · · · · · · · · · · · ·				
ACTESTA NTULEC (D COLD FOUL T)					• • • • • • • • • • •		P					-
GQ152141_N10156/P/2007_PCOV_IA								* * * * * * * * * *			· · · · · · · · · · · · · A	
NC_002306_FIFV_OSA												
DON10000 CD (OF COULT - TTALY			· · · · · · · · · · ·		· · · · · · · · · · · · ·		· · · · · · · · · · · A · · ·					-
DQ112226_CB/05_CCOVIIA_IIADI		1										
KP281485_VACCINE_passage1/clon	· · · · D · · · ·				• • • • • • • • • • •							-
KP281491_VACCINE_passage1/cion			· · · · · · · · · · · ·	• • • • • • • • • • •	· · · · · · · · · · · ·							-
KP281493_VACCINE_passage1/clon												
KP281509_VACCINE_passage3/clon	· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · ·	*********		• • • • • • • • • • • • • •	••••	• • • • • • • • • • • • • • • • • • •	••••	· · · · · · · · · · · · · · ·			
KP281513_VACCINE_passage3/clon		· · · · · · · · · ·				· · · · · · · · · · · ·						
KP281525_VACCINE_passage4/clon										C		
KP281537_VACCINE_passage5/clon	• • • • • • • • • • •	• • • • • • • • • • •	· · · · · · · · · · · ·		• • • • • • • • • • • •	• • • • • • • • • • •	· · · · · · · · · · · · · ·			••••	G	
KP281544_VACCINE_passage6/clon		• • • • • • • • • • • •	· · · · · · · · · · · ·		· · · · · · · · · · · ·	• • • • • • • • • • •			• • • • • • • • • • • • • • •			-
KP281546_VACCINE_passage6/clon					• • • • • • • • • • • • • • • • • • •		· · · · · · · · · · · · · · ·					
KP281583_VACCINE_passage9/clon	G				• • • • • • • • • • •		· · · · · · · · · · ·					-
KP281589_VACCINE_clone119												1.0
KP281591_VACCINE_clone121		* * * * * * * * * * *	• • • • • • • • • • •		*****	* * * * * * * * * *	• • • • • • • • • • • •	*******	• • • • • • • • • • •		*****	$(1, \dots, 1)$
KP281596_master_dominant	• • • • <mark>• •</mark> • • •	• • • • • • <mark>• • •</mark> •	• • • • • • • • • • •	• • • <mark>• • • • • • •</mark> • •	• • • • • <mark>• •</mark> • • •		• • • • • • • • • <mark>• •</mark>	• • • • • • • • • • • •	• • • • • • • • • • • •		· · · · · · · · · · ·	•
	129	0 1300	1310	132	0 133	1340	135	136	0 137	0 1380	0	
	129	0 1300 		132	0 133 1	1340	135	i0 136		0 1380 		
JQ404409_1-71_CCOVIIa_VR-809AT	TSSDFVQIE	GCDVLFVNAT	VIDLPSIIPD	YIDINQTVQD	ILENFRPNWT	VPELPLDIFN	ATYLNLTGEI	NDLEFRSEKL	HNTTVELAIL	IDNINNTLVN	LEWLNRIE	
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE	TSSDFVQIE	GCDVLFVNAT	VIDLPSIIPD	YIDINQTVQD	ILENFRPNWT	VPELPLDIFN	ATYLNLTGEI	NDLEFRSEKL	HNTTVELAIL	IDNINNTLVN	LEWLNRIE	
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_	TSSDFVQIE	GCDVLFVNAT	VIDLPSIIPD	132 1 1 YIDINQTVQD	0 133 ILENFRPNWT Y	VPELPLDIFN	ATYLNLTGEI	0 136 NDLEFRSEKL YI D	HNTTVELAIL	0 1380 IDNINNTLVN	LEWLNRIE	
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU386/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA	TSSDFVQIE	GCDVLFVNAT	VIDLPSIIPD	132 10 10 10 10 10 10 10 10 10 10 10 10 10	0 133 ILENFRPNWT Y	VPELPLDIFN T	ATYLNLTGEI	0 136 	0 127 HNTTVELAIL	0 1380 IDNINNTLVN	LEWLNRIE	
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NIU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068	129 TSSDFVQIE	0 1300 GCDVLFVNAT	VIDLPSIIPD	YIDINQTVQD	• 133	VPELPLDIFN T	ATYLNLTGEI	NDLEFRSEKL YI D	HNTTVELAIL	DNINNTLVN	•I	
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ4773540_K378_CCOVIIa_USA JQ404410_IN-449_CCOVIIa_V82068 EU924790_430/07_CCOVIIB_ITALY	129 TSSDFVQIE	CCDVLFVNAT	vidential states and s	YIDINQTVQD	0 133	UPELPLDIFN	ATYLNLTGEI	D	HNTTVELAIL	DO 138	•I	
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU386/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_UR2068 EU924790_430/07_CCOVIIB_ITALY AY342160_BGF10_CCOVIIA_UK	129 TSSDFVQIE	GCDVLFVNAT	• 1310 • 1 • • • • • • • • • • • • • • • • • •	YIDINQTVQD	0 133	VPELPLDIFN TT	ATYLNLTGEI	0 136 NDLEFRSEKL YI DD	• 137	DO 138	•I	
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIA_IK AY342160_BGF10_CCOVIIA_UK D13096_INSAVC-1_CCOVIA_UK	TSSDFVQIE	GCDVLFVNAT	VIDLPSIIPD 	yidingtvop	0 1333 I LENFRPNWT Y Y	VPELPLDIFN 	ATYLNLTGEI	Diefresekt Diefresekt VI D D	0 137	DININTLVN	LEWLNRIE	
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIB_ITALY AY342160_BGF10_CCOVIIB_ITALY AY342160_BGF10_CCOVIIA_UK EU924791_119/08_CCOVIIA_ITALY	129 TSSDEVQIE	0 1300 GCDVLFVNAT	• 1310 • 1 1 • 1 • 1 • 1 • 1 • 1 • 1 • 1 • 1 •	YIDINQTVQD	0 233	VPELPLDIFN 	ATYLNLTGEI	0 136 NDLEFRSEKL YI DD	0 1377 HNTTVELAIL	DNINNTLVN	LEWLINRIE	
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIA_UK AY342160_BGF10_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_119/08_CCOVIIA_ITALY EU9546361_341/05_COVVII_ITALY	129 TSSDFVQIE	GCDVLFVNAT		YIDINQTVQD	0 133 ILENFRPNWT 		ATYLNLTCEI	0 136 NDLEFRSEKL YI DD	0 137 HNTTVELAIL 		LEWLNRIE	
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ4773540_K378_CCOVIIa_USA JQ404410_IN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIB_ITALY AY342160_BGF10_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_119/08_CCOVIIA_IK EU856361_341/05_COOVII_ITALY EU856362_174/06_COOVII_ITALY	129 TSSDFVQIE	o 1300 GCDVLFVNAT	UIDLPSIIPD	S LIE I YIDINQTVQD	0 1230 1 LENFRPNWT 	0 1340 VPELPLDIFN 	ATYLNLTCEI	D D D D D D D D D D D D D D D D D D D	0 137 HNTTVE LAIL 	0 138	LEWLNRIE	
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIA_UK AY342160_BGF10_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/06_CCOVIIA_UK EU92661_174/06_CCOVII_ITALY EU856362_174/06_COVII_ITALY EU856362_174/06_COVII_ITALY	129	o 1300 CCDVLFVNAT		UDINOTVOD	0 133 ILENFRPNWT 		ATYLNLTGEI	D	0 137 HNTTVELAIL 	0 138		
JQ404409_1-71_CCOVIIa_VR-809AT JF68242_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_IALY EU856361_341/05_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY DQ201447_TS_TGEV_CHINA HQ462571_WH-1_TGEV_CHINA		o 1300 GCDVLFVNAT	S	s 132	0 1233 1 I LENFRPNWT Y Y Y	9 1346 1 1 VPELPLDIFN T T T T T T T T T T TF TF	ATYLNLTGEI	D D D D D D D D D D D D D D D D D D D	• 137 HNTTVE LAIL	0 138 1 1 1 10N INNT LVN		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE QQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_UR2068 EU924790_430/07_CCOVIIa_ITALY AY342160_BGF10_CCOVIIa_UK EU924791_119/08_CCOVIIA_ITALY EU856361_341/05_COOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY DQ201447_TS_TGEU_CHINA HQ462571_WH-1_TGEV_CHINA GQ152141_NTU156/P/2007_FCOV_TA	129	0 1300 GCDVLFVNAT		S III IIII YIDINQTVQD	0 133 I LENFRPNWT - Y - Y - Y - Y - Y - Y - Y	0 1340 	ATYLNLTCEI	0 136 NDLEFRSEKL YI D D D D D D D D D D D D D D D	0 137 HNTTVELAIL 	0 138		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIA_UK AY342160_BGF10_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_119/08_CCOVIIA_ITALY EU856361_341/08_CCOVII_ITALY EU856361_341/08_CCOVII_ITALY EU856361_341/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY BQ201447_TS_IGEU_CHINA HQ462571_WH-1_TGEV_CHINA GQ152141_NTU156/P/2007_FCOV_TA NC_002306_FIPV_USA		9 3300 GCDVLFVNAT	S	9 132	0 1333 1 LENFRONWT 		ATYLNLTGEI	D 1360 NDLEFRSEKL Y D	0 127 HNTTVE LAI L 	2 339		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_USA JQ40410_TN-449_CCOVIIa_UTALY AY342160_BGF10_CCOVIIa_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU95461_341/05_CCOVII_ITALY EU856362_174/06_CCOVII_I		o 1300 GCDVLFVNAT		s 112 YIDINQTVQD	0 1230 1 ILENFRPNWT Y Y Y Y Y Y	3 3340 VPELPLDIFN 	ATYLNLTCEI	0 136 NDLEFRSEKL Y D	0 137 HNTTVE LAIL 	0 138		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK EU924731_119/08_CCOVIIA_ITALY EU856361_341/05_COOVII_ITALY EU856361_341/05_COOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY		9 3300	9 1111 VIDLPSIIPD .E	9 132	0 1333 1 LENFRONWT 	1344 I VPELPLDIFN T T T T T T T T T T T T TF TF TF TF TF TF TF	ATYLNLTGEI	D 1360 NDLEFRSEKL Y D	0 1277 HNTTVE LAIL 	0 1399		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU956361_341/05_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU2201447_TS_TGEV_CHINA HQ462571_WH-1_TGEV_CHINA HQ462571_WH-1_TGEV_CHINA HQ462571_WH-1_TGEV_CHINA HQ462571_WH-1_TGEV_CHINA HQ462571_WH-1_TGEV_CHINA HQ462571_WH-1_TGEV_CHINA HQ462571_WH-1_TGEV_CHINA BQ81789_TGEV_Virulent_Purdue_ DQ112226_CB/05_CCOVIIA_ITALY KP281465_VACCINE_passage1/clon		o 1300 GCDVLFVNAT	9 1311 VIDLPSIIPD 	s 132	0 1233 1 ILENFRPNWT Y Y Y Y Y Y Y Y Y	9 3340 VPELPLDIFN 	ATYLNLTCEI	D IIIE NDLEFRSEKL Y D D D D D D D D D D D D D D D D D	• 117 HNTTVE LAIL	0 138		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIA_UR2068 EU924790_430/07_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_1156/P/2007_FCOV_TA NC_002306_FIPV_USA DQ811789_TGEV_virulent_Purdue_ DQ112226_CB/05_CCOVIIA_UTALY KP281465_VACCINE_passage1/clon		9 3300	9 1301 VIDLPSIIPD 	9 132	0 1333 I LENFRONWT 		ATYLNLTGEI	D 1360 NDLEFRSEKL YT D	0 1277 HNTTVE LAI L 	2 139		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIB_ITALY AY342160_BGF10_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_119/08_CCOVIIA_IXK EU924791_119/08_CCOVIIA_IXLY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU826365_1_WH-1_TGEV_CHINA HQ462571_WH-1_TGEV_CHINA GQ152141_NTU156/P/2007_FCOV_TA NC_002306_FIPV_USA DQ811789_TGEV_VIIA_ITALY KP281485_VACCINE_passage1/clon KP281433_VACCINE_passage1/clon		o 3300		s 132	0 1233 1 ILENFRONWT Y Y Y Y Y Y Y Y		3 133	D 2360 NDLEFRSELL Y D D D D D D D D D D D D D D D D	• 137 HNTTVE LAI L 	2 339		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIA_UK M342160_BGF10_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU356362_174/06_COVII_ITALY EU356362_174/06_COVII_ITALY EU356362_174/06_COVII_ITALY EU356362_174/06_COVII_ITALY EU356362_174/06_COVII_UAA GQ152141_NTU156/F/2007_FCOV_TA NC_002306_FIPU_USA DQ811798_TGEV_VIX0A EQ81526_CB/05_CCOVIIA_UAA EV281491_VACCINE_passage1/clon KP281493_VACCINE_passage1/clon KP281409_VACCINE_passage3/clon		o 1300 GCDVLFVNAT		S 112 YIDINOTVOD	2333 1 LENFRPNWT 	3 3340 VPELPLDIFN 	ATYLNLTCEI	0 136 NDLEFRSELL Y D D D D D D D D D D D D D D D D D	0 137 HNTTVE LAIL 	0 138	0	
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIA_UK AY342160_BGF10_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_119/08_CCOVIIA_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_14_05_CCOVII_ITALY EU856361_150/F2007_FCOV_TA NC_002306_FIPV_USA DQ811789_TGEV_VIrulent_Purdue_ DQ11226_CB/05_CCOVIIA_ITALY KP281405_VACCINE_passage1/clon KP281493_VACCINE_passage1/clon KP281513_VACCINE_passage3/clon		o 3300	S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.	9 132 YIDINQTVQD	o 1333 I LENFRONWT Y Y Y Y Y Y Y Y.		ATYLNLTGE I	D 1980 NDLEFRSEKL Y D.	0 127 HNTTVE LAI L 	2 339		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_109/08_CCOVIIA_UK EU856361_341/05_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU85636_CCOVII_E_Dassage1/clon KP281405_VACCINE_Dassage3/clon KP281505_VACCINE_Dassage3/clon		o 1300 GCDVLFVNAT	9 1311 VIDLPSIIPD 	5 132 YIDINOTVOD	0 1230 1 ILENFRPNWT Y Y Y Y Y Y	9 1346 1 1 1 VPELPLDIFN 	ATYLNLTCEI	0 136 NDLEFRSELL Y D D D D D D D D D D D D D D	0 137 HNTTVE LAIL 	0 138 101 INNTLVM		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_UR2068 EU924790_430/07_CCOVIIA_UR D13096_INSAVC-1_CCOVIIA_UR EU924791_119/08_CCOVII_ITALY EU856361_341/05_COOVII_ITALY EU856361_341/05_COOVII_ITALY EU856361_341/05_COOVII_ITALY EU856361_341/05_COOVII_ITALY EU856361_341/05_COOVII_ITALY EU856361_341/05_COOVII_ITALY EU856361_341/05_COOVII_ITALY EU856361_341/05_COOVII_ITALY EU856361_341/05_COOVII_ITALY EU856361_341/05_COOVII_ITALY EU856361_341/05_COOVII_ITALY EU856361_341/05_COOVII_ITALY EU856361_VH-1_T6EV_CHINA HQ462571_WH-1_T6EV_CHINA CQ152141_NTU166/P/2007_FCOV_TA NC 002306_FIPV_USA DQ811789_T6EV_VIRUENT_Parage1/clon KP281491_VACCINE_pasage3/clon KP281525_VACCINE_pasage3/clon KP281525_VACCINE_pasage4/clon		9 3301	9 1111 1 VIDLPSIIPD .E	9 132 YIDINQTVQD	0 1333 1 LENFRONWT 		ATYLNLTGEI	D 199 NDLEFRSEKL Y D	0 1277 HINTTVE LAI L 	2 129		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIA_UK AY342160_BGF10_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_URA HQ462571_WH-1_TGEV_CHINA HQ462571_WH-1_TGEV_CHINA CC_002006_FIPV_USA DQ811789_TGEV_VIRUENt_Purdue_ DQ11226_CB/05_CCOVIIA_ITALY KP281465_VACCINE_passage1/clon KP281451_VACCINE_passage3/clon KP281533_VACCINE_passage3/clon KP281535_VACCINE_passage3/clon KP281535_VACCINE_passage3/clon KP281535_VACCINE_passage3/clon KP281535_VACCINE_passage3/clon KP281535_VACCINE_passage3/clon KP281535_VACCINE_passage3/clon		o 3300	S	5 122 YIDINOTVOD	0 1230 1 ILENFRPNWT Y Y Y Y Y Y Y Y Y	9 3344 1 1 VPELPLDIFN 	ATYLNLTGEI	D	• 127 HNTTVE LAI L 	5 138 101 INNT LVN		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_USA JQ404410_TN-449_CCOVIIA_UR2068 EU924790_430/07_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_1156/P/2007_FCOV_TA NC_002306_FIPV_USA DQ811789_TGEV_VIIALTALY EV281459_VACCINE_passage1/clon KP281459_VACCINE_passage3/clon KP28153_VACCINE_passage3/clon KP28153_VACCINE_passage3/clon KP28153_VACCINE_passage3/clon KP28153_VACCINE_passage3/clon KP28153_VACCINE_passage5/clon KP281545_VACCINE_passage5/clon KP281545_VACCINE_passage5/clon KP281545_VACCINE_passage5/clon		9 3300	9 1111 VIDLPSIIPD .E	9 132 YIDINQTVQD	0 1333 I LENFRONWT Y		ATYLNLTGEI	D	0 127 HINTTVE LAI L 	2 129		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIB_ITALY AY342160_BGF10_CCOVIIA_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_119/08_CCOVIIA_ITALY EU856361_341/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU856362_174/06_CCOVII_ITALY EU85636_COVII_TALY DQ201447_TS_TGEV_CHINA HQ462571_WH-1_TGEV_CHINA GQ152141_NTU156/P/2007_FCOV_TA NC_002306_FIPV_USA DQ811789_TGEV_VITULENT_Purdue_ DQ12226_CE/05_CCOVIIA_ITALY KP281465_VACCINE_passage1/clon KP281509_VACCINE_passage3/clon KP281531_VACCINE_passage3/clon KP281531_VACCINE_passage4/clon KP281544_VACCINE_passage4/clon KP281544_VACCINE_passage6/clon KP281544_VACCINE_passage6/clon		o 3300	S	9 132 YIDINQTVQD	0 1333 1 LENFRONWT Y Y Y Y Y Y Y Y		5 133	D	0 137 HNTTVE LAI L 	2 338		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_USA JQ404410_TN-449_CCOVIIA_UR2068 EU924790_430/07_CCOVIIB_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_10/08_CCOVIIA_UK EU924791_10/08_CCOVIID_ITALY EU856361_341/05_CCOVIID_ITALY EU856362_174/06_CCOVIID_ITALY EU856362_174/06_CCOVIID_ITALY EU856362_174/06_CCOVIID_ITALY EU856362_174/06_CCOVIID_ITALY EU856362_174/06_CCOVIID_ITALY EU856362_174/06_CCOVIID_ITALY EU856362_174/06_CCOVIID_ITALY EU856362_174/06_CCOVIID_ITALY EU856362_174/06_CCOVIID_ITALY EU856362_174/06_CCOVIID_ITALY EU856362_COVIDE_PASSage1/clon KP281493_VACCINE_passage1/clon KP281543_VACCINE_passage3/clon KP281535_VACCINE_passage3/clon KP281535_VACCINE_passage3/clon KP281546_VACCINE_passage3/clon KP281546_VACCINE_passage3/clon KP281546_VACCINE_passage3/clon KP281546_VACCINE_passage3/clon KP281546_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon		S 330	9 1301 VIDLPSIIPD .E	9 132 YIDINQTVQD	0 1333 I LENFRONUT Y		ATYLNLTGEI	D 198 NDLEFRSEKL YT D.	0 127 HNTTVE LAI L 	2 139		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_VR2068 EU924790_430/07_CCOVIIB_ITALY AY342160_BGF10_CCOVIIA_UK EU924790_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_341/05_CCOVII_ITALY EU856361_000_CCOVII_ITALY EU856361_000_CCOVII_ITALY EU85636_CCOVII_ITALY EU85636_CCOVII_ITALY KP281405_VACCINE_passage1/clon KP281503_VACCINE_passage3/clon KP28153_VACCINE_passage3/clon KP28153_VACCINE_passage3/clon KP28153_VACCINE_passage3/clon KP28153_VACCINE_passage3/clon KP281544_VACCINE_passage3/clon KP281543_VACCINE_passage3/clon KP2815		o 3300	S	9 132 YIDINQTVQD	o 1333 I LENFRONWT Y Y Y Y Y Y Y Y.		A TYLNLTGE I	D	0 127 HNTTVE LAI L 	2 339		
JQ404409_1-71_CCOVIIa_VR-809AT JF682842_NA/09_CCOVII_GREECE GQ477367_NTU336/F/2008_CCOVII_ KC175340_K378_CCOVIIa_USA JQ404410_TN-449_CCOVIIa_UXA AY342160_BGF10_CCOVIIa_UK D13096_INSAVC-1_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/08_CCOVIIA_UK EU924791_119/06_CCOVIIA_UK EU924791_119/06_CCOVIIA_UK EU924791_119/06_CCOVIIA_UK EU356362_174/06_CCOVIIA_UTALY DQ201447_TS_TGEV_CHINA HQ462571_WH-1_TGEV_CHINA GQ152141_NTU156/P/2007_FCOV_TA NC_002306_FIPV_USA DQ811798_TGEV_VIXULENT_Purdue_ DQ811798_TGEV_VIXULENT_PURDUE DQ81198_TGEV_VIXULENT_PURDUE PQ81493_VACCINE_passage1/clon KP281549_VACCINE_passage3/clon KP281543_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP28154_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon KP281545_VACCINE_passage3/clon		CCDVLFVNAT	9 100 VIDLPSIIPD .E	5 122 YIDINOTVOD	0 1230 1 ILENFRPNWT 	9 3345 VPELPLDIFN 	ATYLNLTGEI	D D D D D D D D D D D D D D D D D D D	0 137 HNTTVE LAIL 			

4. Discussion

The 1-71 strain of CCoV adapted in A72 cells showed mutations transitions, transversions and deletions but in a low number and without a passage-association pattern, what might indicate that this strain in this study may have reached a quite stable virus-cell relationship with no further mutations being fixed even after serial passages, as it had been previously adapted to grow in A72 cells.

Selection pressure can be indicated by frequency of silent and non-silent mutations. Usually surface proteins present mostly non-silent mutations as a result of immunological pressure, while internal proteins mostly show silent changes (Truyen et al., 1995).

Taking this into account, the amplified region of the *S* gene (S2) in this study is responsible for membrane fusion and syncytia formation and has a higher mutation pressure than region S1, responsible for binding to cellular receptors (Lai And Cavanagh 1997). Nevertheless, mutations were found also in S2 region (Gallagher and Buchmeier, 2001) and evolutionary studies of other coronavirus showed that mutations in the S2 subunit can allow virus entry into a variety of types of cells in a trypsin-independent way (Belouzard, Chu and Whittaker 2009; Borucki et al, 2013). Amino acid substitutions occurred mainly at the center of the sequence, and the deletion, which may suggest that this area has a lower selective pressure.

Other factors that could justify not repeat mutants are these could already be preselected and were extinct, or gained in strength and after weighed, or may have been biased sampling of clones. Instability of spike protein is a disadvantage in vitro because stabilized variant are selected (Gallagher and Buchmeier, 2001).

Since the dominant strain is stable and adapted to a new host cell, adaptation is a rapid process (Fang et al., 2005) and thus the master sequences may have been as a result of this

stability. Conversely, in the case of field strains, on e need to take into account that there's interference during co-infection with CCoV I, Feline coronavirus (FCoV) and Transmissible Gastroenteritis Coronavirus (TGEV) as inter-types recombination is a well known phenomenon for these viruses (Decaro et al. 2009, Decaro 2010; Vennema, 1999).

Far beyond the clinical level, evolution and genetic studies of coronavirus modeled the CCoV allow the understanding of basic virology and the evolution of these viruses more broadly, generating data that can serve as a basis for studies in other coronavirus species including those that affect humans, as cold-causing coronavirus OC43 and 229E and the coronavirus associated with the syndrome severe acute (SARS) respiratory.

5. Conclusion

Cell-adapted CCoV-II vaccine strains may be highly genetically stable after serial passages in a same cell line, accumulating mainly synonymous nucleotide substitutions in the spike gene due to a stable cell-host relationship.

Conflict of interest

None

Acknowledgments

The work was supported by CNPq (grant # 301225/2013-3) and FAPESP (grant#2010/19399-2) and approved by the Bioethics Comission of the School of Veterinary Medicine and Animal Science of the University of São Paulo (protocol number # 2188/2011).

References

Belouzard, S., Chu, V.C., Whittaker, G.R. 2009. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proceedings of the National Academy of Sciences of the United States of America. 106 (14), 5871–5876.

Borucki, M. K., Allen, J. E., Chen-Harris, H., Zemla, A., Vanier, G., Mabery, S., Torres, C., Hullinger, P., Slezak, T. 2013. The role of viral population diversity in adaptation of bovine coronavirus to new host environments, PLoS ONE, 8 (1), 1-11.

Bosch, B.J., Van Der Zee, R., De Haan, C.A.M., Rottier, P.J.M, 2003. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. Journal of Virology, 77, 8801-8811.

Buonavoglia, C., Decaro, N., Martella, V., Elia, E., Campolo, M., Desario, C., Castagnaro,M., Tempesta, M., 2006. Canine coronavirus highly pathogenic for dogs. Emerging InfectiousDiseases.12, 492-494.

Carstens, E.B., 2010. Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2009). Archives of Virology. 155, 133–146.

Decaro, N., Martella, V., Elia, G., Campolo, M., Desario, C., Cirone, F., Tempesta, M., Buonavoglia, C. 2007. Molecular characterization of the virulent canine coronavirus CB/05 strain. Virus Research, 125, 54–60. Decaro, N., Buonavoglia, C. 2008. An update on canine coronaviruses: viral evolution and pathobiology. Veterinary Microbiololgy 132 (3-4), 221–234.

Decaro N., Mari V., Campolo M., Lorusso A., Camero M., Elia G., Martella V., Cordioli P., Enjuanes L., Buonavoglia C., 2009. Recombinant canine coronaviruses related to transmissible gastroenteritis virus of Swine are circulating in dogs. Journal of Virology. 83, 1532-1537.

Decaro, N., Mari, V., Elia, G., Addie, D.D., Camero, M., Lucente, M.S., Martella, V., Buonavoglia, C., 2010. Recombinant canine coronaviruses in dogs, Europe. Emerg Infect Dis. 16, 41-47.

Fang, S.G., Shen, S., Tay, F.P.L., Liu, D.X. 2005. Selection of and recombination minor variants lead to the adaptation of an avian coronavirus to primate cells. Biochemical and Biophysical Research Communications, 336, 417-423.

Gallagher, T.M., Buchmeier, M.J., 2001. Minireview Coronavirus spike proteins in viral entry and pathogenesis. Virology, 279, 371-374.

Guirao, M.P., Souza, S.P., Jerez, J.A., Richtzenhain, L.J., Brandao, P.E., 2013. Phylogeny of canine coronavirus (CCoV) from Brazilian dogs based on membrane protein partial sequences. Arq. Bras. Med. Vet. Zootec. 65, 1887-1890.

LAI, M. M. C.; CAVANAGH, D. 1997. The molecular biology of coronavirus. Advances in Virus Research, 48, 1-100.
Makino, S.; Keck, J. G.; Stohlman, S. S.; Lai, M. M. C. 1986. High frequency RNA recombination of murine coronavirus. Journal of Virology, 57, 729-739.

Masters, P.S., Perlman, S., 2013 *Coronaviridae. In:* KNIPE, D.M.; HOWLEY, P.M.; Fields Virology, Lippincott Williams & Wilkins, Philadelphia, Pa. 1, 825-858.

Pratelli, A., Decaro, N., Tinelli, A., Martella, V., Elia, G., Tempesta, M., Cirone, F., Buonavoglia, C., 2004. Two genototypes of canine coronavirus simultaneously detected in the fecal camples of dogs with diarrhea. Journal of Clinical Microbiology, 42, 1797-1799.

Pratelli, A., 2006. Genetic evolution of canine coronavirus and recent advances in prophylaxis. Veterinary Research. 37, 191-200.

Vennema, H. 1999. Genetic drift and genitc shift during feline coronavirus evolution. Veterinary Microbiology. 69, p. 139-141.

Truyen, U., Parrish, C.R., Harder, T.C., Kaaden, O-R. 1995. There is nothing permanent except change. The emergence of new virus diseases. Veterinary Microbiology, 45, 103-122.

IV. Genera Conclusions

Phylogenetic analysis based of M gene of CCoV is a useful tool for typing, however not for sub typing CCoV strains. N gene of CCoV is highly conserved with a lower tree resolution regarding trees based on the M and S genes. Regarding the 3b gene, CCoVs types I and II show a low polymorphism and no stable markers for type differentiation in the 3bsegment under analysis in this study.

A putatively pantropic Brazilian CCoV type II strain was isolated in canine cells causing a syncytial CPE, with no CCoV-I isolation, suggesting that CCoV type II is more readily isolated when compared to type I.

Cell culture-adapted CCoV-II vaccine strains may be highly genetically stable upon serial passage in a same cell line, accumulating primarily synonymous nucleotide substitutions in the spike gene due to a stable cell-host relationship.

In short, all data gathered herein on molecular epidemiology and evolutionary processes of CCoV can serve for a better understanding of basic virology and as a basis for studies on other coronaviruses. Further cloning and sequence analysis of more genes of CCoV are ongoing in order to understand the *in vitro* evolution and molecular epidemiology of canine coronavirus.